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Abstract
The eggs of Xenopus laevis frogs have been used extensively to study various
aspects of chromatin biology. In this document, we characterize two novel systems to
study transcription (Chapter 2) and DNA double strand break repair (Chapter 4) utilizing
different egg extracts. Notably, we show that nucleoplasmic extract is the first
established Xenopus egg extract to support RNA polymerase II-mediated transcription of
plasmid-borne gene constructs. Using this cell-free transcription system, we provide the
first evidence of a molecular connection between the tumor suppressor, BRCA1, and the
major epigenetic regulator, BRD4 (Chapter 3). We show BRCA1, along with its
constitutive binding partner BARD1, negatively regulates the DNA-binding of BRD4. This
mechanism likely involves the acetylation of histone H4K8, a known substrate for BRD4binding, as this mark is increased in the absence of BRCA1. Furthermore, we identify
and characterize a novel system for double strand break repair in extract. Importantly,
we show that in this system, broken DNA ends are repaired by both non-homologous
end joining as well as homologous recombination, similar to the established literature.
We then use this system to show that BRD4 plays a role in homology-directed repair that
is independent to its established role in transcription regulation (Chapter 4). Notably, we
establish a direct interaction between BRD4 and two major DNA repair proteins, CtIP
and BRG1. Loss of BRD4 results in reduced recruitment of each of these proteins to
damaged DNA, and ultimately reduces DNA end resection and subsequent homologous
recombination repair.
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Chapter 1: Introduction

1.1 Xenopus Egg Extracts: A Model System
The African clawed frog, Xenopus laevis, has long been utilized as a model
system to study various aspects of biology(1). These animals require little maintenance
and are relatively inexpensive to house. Additionally, these vertebrates contain higher
evolutionary homology than more advanced species, such as humans, compared to
other traditional model organisms such as worms, zebra fish and yeast.
The most utilized product of Xenopus laevis in the scientific community is their
eggs. Female frogs can lay up to 1,000 eggs per spawning and can be induced to lay
multiple times throughout the year. These unfertilized eggs are protected by a jelly coat
and contain a concentrated mixture of protein and nucleic acid needed for rapid
development.

1.1a Overview of Xenopus development and egg extracts
During the development of Xenopus, mature eggs are fertilized externally. This
single-cell embryo undergoes multiple rounds of rapid DNA synthesis and cellular
division to form a fluid-filled sphere of cells called a blastula. This process relies heavily
on maternally-deposited proteins and mRNA found in mature eggs, as most transcription
from the zygotic genome is repressed at early stages of development(2). After several
rounds of cellular division, the zygotic genome transitions to a transcriptionally active
state through a process referred to as the mid-blastula transition (MBT)(3). The MBT
allows each cell in the blastula to mass-produce necessary proteins needed for further
development. Several models have been proposed as to how zygotic genome activation
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is achieved(4), but a prevailing mechanism revolves around histone deposition. DNA is
bound by histones to form chromatin, which supports DNA compaction and acts as a
scaffold for regulating various aspects of transcription(5, 6). During early embryo
development, the concentration of maternal histones remains constant. However, each
round of DNA synthesis increases the ratio of DNA to histones. As histones become
limiting, promoter elements throughout the genome are thought to become more
accessible to transcription factors that trigger a wave of transcriptional activity at the
MBT.
Many laboratories utilize protein extracts derived from Xenopus laevis eggs.
These extracts are produced in different ways to mimic various stages of Xenopus
development (Figure 1.1). “Traditional” extracts are produced with mature, unfertilized
Xenopus eggs. These eggs can be driven to interphase by the addition of exogenous
calcium (Ca2+), which mimics the release of calcium generated during fertilization(7).
Some extracts derived from interphase-arrested eggs can promote chromatin
decondensation and nuclear formation(8). Unfertilized eggs can also be lysed in the
presence of a calcium chelator (EGTA) to induce a mitotic state. Extracts have also been
produced with immature oocytes isolated from frog ovaries (arrested in prophase I). A
nucleoplasmic extract (NPE) was developed by isolating the nuclei formed when
Xenopus sperm chromatin is incubated in extract derived from interphase eggs(9).

1.1b Use of Xenopus egg extract to study chromatin biology
Soluble extracts prepared from Xenopus eggs have been used extensively to
study various aspects of cellular and developmental biology, including nuclear
formation(10-12), DNA replication and repair(13-16), cellular and checkpoint
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Figure 1.1. Schematic of Xenopus laevis egg extracts prepared at different developmental stages. CSF
(cytostatic factor-arrested extract), LSS (low-speed supernatant of interphase eggs), HSS (high-speed
supernatant of interphase eggs), NPE (nucleoplasmic extract).
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signaling(17-20), mitosis(21-23), and apoptosis(24). A major breakthrough was the
production of NPE(9), as this extract in combination with interphase extract promotes
replication of plasmid-borne substrates in the absence of a nucleus. Studies have used
this system to uncover novel insights into replication-coupled DNA repair and replication
termination. It is important to note, as extracts are produced from eggs that are in a
transcriptionally inactive state, traditional egg extracts do not support widespread
transcription. Thus, study of transcription, a fundamental biological process, has been
precluded from this model system.

1.2 The Breast and Ovarian Cancer Susceptibility Gene 1 (BRCA1)
Germline mutations within the BRCA1 gene confer ~80% lifetime risk of developing
breast cancer and ~50% lifetime risk of developing ovarian cancer(25). Additionally,
sporadic cases of breast cancers have been shown to silence expression of BRCA1,
allowing tumor progression(26). Molecularly, BRCA1 has been described as a master
regulator of genome integrity. Notably, BRCA1 has various roles in the DNA damage
response and is required for homologous recombination (HR), which allows error-free
repair of DNA double-strand breaks(27). These observations established BRCA1 as a
tumor suppressor; however, the mechanism behind the tissue-specificity of BRCA1mutant tumors remains elusive. Surprisingly, BRCA1 is involved in a multitude of other
cellular processes beyond its function in DNA repair, including cell cycle control, mitotic
spindle formation, ubiquitination, and transcription regulation(28). The role of BRCA1 in
these cellular functions is less clear, and understanding how BRCA1 is involved in these
processes could provide valuable insight into its role as a tumor suppressor.
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1.2a Structure and function of BRCA1
Human BRCA1 encodes a 1,863 amino acid protein with three highly conserved
functional domains: an N-terminal RING (Really Interesting New Gene), a central coiled
coil, and C-terminal tandem BRCT (BRCA1 C-terminal) domains (Figure 1.2). The RING
domain forms a functional E3 ligase through its interaction with the BRCA1-associated
RING domain protein 1 (BARD1)(29). The stability and nuclear localization of BRCA1 is
dependent on its interaction with BARD1(30). Clinical mutations abrogating this
interaction are highly correlated with breast and ovarian tumorigenesis; however, it has
been argued that BRCA1’s E3 ligase function is dispensable for tumor suppression(31).
The coiled coil domain is most notable for its interaction with the partner and localizer of
BRCA2 (PALB2), a protein that facilitates the interaction between BRCA1 and BRCA2 in
HR(32). Clinical mutations in this domain promote deficiencies in DNA repair(33).
Finally, the C-terminal tandem BRCT domains promote interactions with serinephosphorylated proteins(34). This domain is considered a major factor in localizing
BRCA1 to DNA.

1.2b Functions of BRCA1 in DNA repair
BRCA1 is most known for its central role in coordinating DNA repair. BRCA1 was
initially implicated in the DNA damage response when it was found to co-localize to
damage-induced foci along with the repair protein RAD51(35). Studies identified the
proteins Abraxas and RAP80 (receptor-associated protein 80) as major coordinators of
BRCA1 to sites of DNA damage(36). As the functions of BRCA1 in DNA repair grew, as
well as its known binding partners, researchers developed a nomenclature for distinct
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Figure 1.2. Schematic of human BRCA1. BRCA1 contains three major functional domains, and N-terminus
RING domain, a central coiled-coil domain, and tandem BRCT domains at its C-terminus. Binding partners to each
domain often dictate the molecular function of the complex.
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BRCA1-containing protein complexes. The BRCA1-Abraxas-Rap80 complex, having a
central role in recognizing DNA double strand breaks, is denoted as the BRCA1-A
complex. The BRCA1-B complex plays a role in preserving genome integrity throughout
S phase, primarily through controlling replication checkpoints. Proteins involved in this
complex include FANCJ/BACH1 (BRCA1-interacting protein carboxy-terminal helicase
1) and TOPBP1 (topoisomerase II-binding protein I)(37, 38). A third complex, BRCA1-C,
has a major function in DNA end resection and contains CtIP (C-terminal-binding protein
interacting protein) and the MRN complex (MRE11-RAD50-NBS1)(39, 40). A fourth
complex, given the name BRCC due to interactions in the coiled coil domain of BRCA1,
promotes HR-mediated DNA repair. Essential proteins for this function include PALB2
and BRCA2, which together with BRCA1 help load RAD51 filaments onto single
stranded DNA(32, 41). There are protein redundancies between these complexes, but
collectively they showcase the many functions BRCA1 has in preserving genome
integrity.

1.2c Functions of BRCA1 outside of DNA repair
BRCA1 has been implicated in a variety of cellular processes, including
transcription regulation, cell cycle control, ubiquitination, and chromatin modification(42).
Many of these functions are dependent on DNA damage signaling and often dictated by
interactions with various cofactors. Recently, BRCA1 has been shown to act as a cotranscriptional regulator. Since BRCA1 contains no clear DNA binding domain, it is
thought to influence transcription primarily through interactions with other proteins,
including traditional transcription factors(43). As with several transcription regulators,
BRCA1 has been implicated in both gene activation and suppression. Furthermore,
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studies have identified BRCA1-containing complexes in both global and gene-specific
mechanisms of transcription regulation(42).
A prevailing mechanism for BRCA1’s role in transcription regulation stems from
its sole enzymatic activity as a functional E3 ligase with its cognate binding partner
BARD1. Several BRCA1-BARD1 substrates involved in transcription have been
identified in vitro, including RNA polymerase II (RNAPII), TFIIE and histone H2A(44-46).
Histone H2A ubiquitination has been associated primarily with transcriptional
silencing(47-49), and BRCA1’s function in this modification may contribute to its role in
preserving genome integrity. Additionally, BRCA1-dependent ubiquitination of basal
transcription factor, TFIIE, has also been associated with transcription suppression(46).
Conversely, several reports have identified BRCA1 as a global activator of
transcription(50, 51). These conflicting reports highlight the importance of clearly
defining the molecular role(s) of BRCA1 in transcription regulation. Furthermore,
understanding how BRCA1’s E3 ligase function contributes to transcription regulation
remains a critical area of study.

1.3 The bromo- and extraterminal domain (BET) family of proteins
1.3a Structure and function of BET proteins
BET proteins are established epigenetic regulators that have multiple functions in
transcription regulation (reviewed in (52)). The BET family of proteins contains
ubiquitously expressed BRD2, BRD3, and BRD4, as well as testis-specific BRDT. Often
bound to active gene promoters, BET proteins promote the recruitment of multiple
protein complexes involved in transcription initiation and elongation. All proteins in the
BET family contain N-terminal tandem bromodomains (BD), which bind acetylated lysine
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residues to facilitate protein-protein interaction (Figure 1.3). The BDs of BET proteins
often bind acetylated-lysine residues on the tail of histone H4, which localizes BET
proteins to DNA; however, the BDs can also bind other acetylated proteins(53). In
addition to BDs, all family members contain an extraterminal (ET) domain that helps
recruit different proteins responsible for transcription regulation(54). Two of the BET
proteins, BRD4 and BRDT, also contain a C-terminal domain (CTD). This domain has
been shown to promote recruitment of the positive elongation factor (P-TEFb), a critical
regulator in promoting transcription elongation(55). BRD4 also contains an irregular
histone acetyltransferase (HAT) domain(56), responsible for conjugating acetyl marks
onto target proteins. Additionally, BRD2 and BRD4 contain kinase domains, which
promote phosphorylation of various substrates including RNAPII(57, 58). Neither HAT
nor kinase domains have been identified in the remaining BET proteins. Notably,
homozygous deletion of BRD2 or BRD4 is embryonic lethal(59, 60), suggesting a
fundamental role of BET proteins in development.

1.3b Targeting BET proteins as therapeutics for cancer treatment
BET proteins control the transcription of several proliferation genes and
established oncogenes, such as c-MYC(61). Additionally, several human cancers
overexpress BRD2 or BRD4(62, 63). Specifically, BRD4 plays a critical role in promoting
a certain type of rare, aggressive cancer called NUT carcinoma. This malignancy is
genetically defined by a chromosomal rearrangement between the NUT gene and
BRD4, creating a BRD4-NUT oncogene.
BET inhibition has become an attractive target for therapeutic intervention in
several cancer subtypes. One of the first established BET inhibitors was JQ1,
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Figure 1.3. Domain organization of BET proteins. The BET family of proteins are often recruited to DNA
through the interaction of their BD domains and acetylated lysine residues on histone proteins. The ET and CTD
domains facilitate further protein interactions, often important for transcriptional regulation.

12

discovered in 2010(64). This drug, and similar ones to follow, inhibit the DNA localization
of BET proteins by mimicking an acetylated lysine residue and specifically binding their
BDs. Treatment with BET inhibitors dramatically changes the transcriptome and
promotes global displacement of BET proteins from gene enhancer and promoter
regions. Although no BET inhibitors are currently approved by the FDA, there are
several in ongoing Phase I/II clinical trials. The results of these trials will determine the
efficacy of BET inhibitors for cancer treatment.

1.3c BRD4 and DNA repair
BRD4 is the most extensively studied BET protein, and increasing evidence has
implicated this protein in cellular processes outside transcription regulation. Notably,
BRD4 has been implicated in cell cycle control, telomere maintenance, and DNA repair
(reviewed in (65)). The role of BRD4 in these processes has been difficult to establish,
due to its established role in transcription regulation. For example, inhibition or genetic
silencing of BRD4 results in deficiencies in homologous recombination (HR), a form of
error-free DNA repair(66-69). However, many proteins with fundamental roles in HR,
such as BRCA1, RAD51 and CtIP, are downregulated when BRD4 is inactivated. As
such, transcriptome dysfunction may provide a barrier to identifying novel functions of
BRD4, or other BET proteins, in DNA repair.
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Chapter 2: Nucleoplasmic extract supports RNAPII-mediated
transcription

Sections from Chapter 2 were previously published in the Journal of Biological
Chemistry, an American Society for Biochemistry and Molecular Biology journal, with
permissions and contributions from authors John K. Barrows and David T. Long.

2.1 Premise
Extracts derived from the eggs of Xenopus laevis have been used for
foundational studies in many areas of chromatin biology. However, these extracts have
been found to possess little or no intrinsic transcriptional activity(70), limiting study of a
fundamental biological process with this model system. The lack of transcription activity
is likely due to the inherent properties of the eggs in which these extracts originate.
Unfertilized eggs completely lack transcriptional activity, and do not rely on transcription
of the zygotic genome until after several rounds of DNA synthesis and division(2). It is
largely accepted that transcription activation is dependent on the ratio of DNA to
histones, where the eventual reduction in histones after subsequent cellular divisions
allows transcription factor and polymerase binding to DNA(71-73).
Previously, a nucleoplasmic extract (NPE) was developed by isolating the nuclei
formed when Xenopus sperm chromatin is incubated in extract derived from interphase
eggs(9). NPE supports highly efficient chromatinization and synthesis of plasmid DNA
substrates, and has led to seminal discoveries in DNA replication and repair(74-78).
However, the transcriptional activity of NPE has not been determined. Although
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prepared from eggs in a transcriptionally inactive state, the process of making NPE
resembles that of egg fertilization and early embryo development that leads to
transcriptional activation.
In Chapter 2, we demonstrate that NPE readily supports transcription from
endogenous gene elements on a naturally chromatinized plasmid substrate. Promoterdependent recruitment of transcription factors and RNA polymerase II (RNAPII) leads to
conventional patterns of divergent transcription and pre-mRNA processing, including
intron splicing and 3’ cleavage and polyadenylation. We also show that histone density
regulates transcription in NPE by limiting the recruitment of transcription factors to DNA,
validating a mechanism proposed to control genome activation during early
development. Together, these results establish a new cell-free system that supports
multiple mechanisms involved in the regulation, initiation, and processing of mRNA
transcripts.

2.2 Methods and Materials
Plasmid Substrates
The parent pCMV vector was purchased from Addgene (#11153). The 5’ and 3’ regions
of actb were amplified from Xenopus laevis sperm chromatin (prepared as described in
(7)) using the following primer pairs:

5’ region:

CAGGAACTAGTAGAACAGGGAAGCAATGGAT and
TAGACCATGGTGGCCTGAAAAGAGAATTAGATT

3’ region:

ATAGCGGCCGCAGGACAGACCCTTTCAACATG and
GCGCTGCCTAGGTTTGTTTGAGTGCACCACC
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The resulting fragments were then cloned into pCMV using SpeI and NcoI (5’ region), or
NotI and AvrII (3’ region). The carrier plasmid (pCarrier) utilized in Figure 2.2E was a
pFastBac1 vector (Thermo Fisher) carrying the Xenopus BARD1 gene(79). To generate
the ΔPromoter plasmid, actb core promoter elements were deleted by site-directed
mutagenesis (Agilent Technologies) using the following primers:

Forward: CTTCGTCCGCAGTTCCTACGTCCAACCCTCAGGC
Reverse: GCCTGAGGGTTGGACGTAGGAACTGCGGACGAAG

The enhancer region of pCMV was amplified using the following primers:

CATTGTCGACCGTTACATAACTTACGGTAAATGGCC and
GCGTACTAGTCATGGTAATAGCGATGACTAATACGTAGAT

The resulting fragment was cloned into pActin using SalI and SpeI to create pE-Actin.

Incubation in Xenopus egg extract
High speed supernatant (HSS), cytostatic factor arrested (CSF), and nucleoplasmic
(NPE) extracts were produced as described previously(7, 9). In all reactions, extracts
were supplemented with ATP regenerating mix (6.5 mM phosphocreatine, 0.65 mM
ATP, and 1.6 µg/mL creatine phosphokinase). NPE was also supplemented with 1 mM
DTT, and CSF was supplemented with 0.3 mM Ca2+ to promote entry into interphase.
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Reactions were incubated at 21°C for 10 minutes prior to the addition of plasmid DNA,
which represents 0 minutes. Where indicated, extracts were supplemented with [α-32P]
UTP to label nascent RNA, or 10 µM α-amanitin to inhibit RNAPII. All experiments were
performed at least two times with representative or averaged data shown.

UTP Incorporation Gels
Three hours after addition of plasmid DNA to each extract, samples were withdrawn
from the reaction and added to Stop Buffer (3.6% SDS, 18 mM EDTA, 90 mM Tris-HCl,
9% Ficoll). Samples were then mixed with RNA Gel Loading Dye (Thermo Fisher),
incubated at 65°C for 20 minutes, and resolved by agarose gel electrophoresis.
Radiolabeled transcripts were visualized and quantified using a phosphorimager.

Reverse Transcription Quantitative PCR (RT-qPCR)
RNA was isolated from extract using the EZNA RNA Purification kit (Omega Bio-tek) and
cDNA was generated using the QuantiTect Reverse Transcription kit (Qiagen). Samples
were then analyzed by quantitative real-time PCR with the following primer pairs:

Control:

CCCAACCAGTGTTACACCACTTCC and
ATGCCTGGGAGCGGCCTTAT

Promoter:

TATGGGCTGCATGAAATGG and AATTGCGCGACCTACAACTC

Elongation:

GCGCTTTACGTTAGCAATCC and AGGCTTTCAGTGAGCCAGTC

pCMV Promoter: AGCTGGACGGCGACGTAAAC and CCTCGTGACCACCCTGACCT
pCMV Elongation: GGTGAACTTCAAGATCCGCCA and TGCCCGACAACCACTACCTG
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Unspliced:

GCGGGTCCTCACCTTCAATCTAATTCTC and
TCGCCGGACACGCTGAACTT

Spliced:

TCCAACCCTCAGGCCACCAT and TCGCCGGACACGCTGAACTT

Uncleaved:

CACATCTGTTTCTTGCTATGAGGTG and
CAAAACCCATTCATTTTGCCA

Cleaved:

CACATCTGTTTCTTGCTATGAGGTG and
TTTTTTTTTTTTTTTTTTTTGCCA

18S rRNA:

GACCGGCGCAAGACGAACCA and TGCTCGGCGGGTCATGGGAA

To quantify RNA processing, the level of nonspecific amplification of spliced and cleaved
primers was determined using a pActin standard curve, which only contains unspliced
and uncleaved sequences. The background amplification was then subtracted from each
sample based on the level of total unprocessed RNA present in that sample. PCR
fragments containing spliced or cleaved sequences were also generated using the
spliced and cleaved primer pairs to create a standard curve for processed samples.
To identify cleavage and polyadenylation sites downstream of the actb promoter, pActin
was incubated in NPE for 120 minutes at 5 ng/µL and cDNA was generated as
described above. Cleaved and polyadenylated transcripts were amplified by PCR with
the following primers:

Forward Primer:

GGGCTCATTCTCTTTAACATCTGGAAG

Anchored Oligo(dT)20: TTTTTTTTTTTTTTTTTTTTVN (Integrated DNA Technologies)
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PCR reaction products were then resolved by agarose gel electrophoresis, purified using
a gel extraction kit (Qiagen), and sequenced (Genewiz).

Chromatin Immunoprecipitation (ChIP)
ChIP was preformed as described previously(80). Briefly, reaction samples were
crosslinked in Egg Lysis Buffer (ELB: 10 mM HEPES-KOH pH 7.7, 2.5 mM MgCl2, 50
mM KCl, and 250 mM sucrose) containing 1% formaldehyde. Crosslinking was stopped
by the addition of 125 mM glycine, and formaldehyde was removed using a Micro BioSpin 6 chromatography column (Bio-Rad). Samples were then sonicated (Diagenode
Bioruptor UCD-600 TS) and immunoprecipitated with the indicated antibody. Following
immunoprecipitation,

crosslinks

were

reversed

and

DNA

was

isolated

by

phenol/chloroform extraction and ethanol precipitation. Total (INPUT) and recovered
DNA were then analyzed by qPCR using the following primer pairs:

pActin:

CCTCCTTCGTCCGCAGTTCC and GCTGGCGAACCGCTACTTGC

ΔPromoter:

GAAAATACGGGGCGTGGAAGATT and GCTGGCGAACCGCTACTTGC

Micrococcal Nuclease Digestion
pActin was incubated in NPE at 10, 25, or 100 ng/µL for 60 minutes at 21°C. Equal
amounts of pActin were withdrawn from each reaction and mixed with 1x Micrococcal
Nuclease Reaction Buffer (New England Biolabs). Additional NPE was also added to the
25 and 100 ng/µL mixes so that all three treatments contained equal amounts of DNA
and extract. 100 units of micrococcal nuclease (New England Biolabs) was then added
and reactions were incubated at 37°C. At the indicated time, samples were withdrawn,
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mixed with an equal volume of STOP Buffer, and then treated with proteinase K
(ThermoFisher) for 120 minutes at 37°C. Undigested DNA was then resolved by agarose
gel electrophoresis and visualized with SYBR Gold stain.

Plasmid Pull-Down
Plasmids were isolated from NPE as described previously(80). Briefly, reaction samples
were withdrawn at the indicated time and added to LacI-coupled magnetic beads
(Dynabeads M-280; Invitrogen) suspended in LacI pull-down buffer (10 mM HEPES pH
7.7, 2.5 mM MgCl2, 50 mM KCl, 250 mM sucrose, 0.25 mg/mL BSA, and 0.02% Tween
20). Samples were incubated for 20 minutes, rotating at 4°C. Beads were then washed
three times with LacI wash buffer (10 mM HEPES pH 7.7, 2.5 mM MgCl2, 50 mM KCl,
0.25 mg/mL BSA, and 0.02% Tween 20), dried, and suspended in 2X SDS sample
buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, and
200 mM β-mercaptoethanol). DNA-bound proteins were then resolved by SDSpolyacrylamide gel electrophoresis and visualized by Western blotting with the indicated
antibodies.

Antibodies and Immunodepletion
RNA polymerase II antibodies were purchased from Bethyl Laboratories (A300-653A for
Western, A304-405A for ChIP). TATA-binding protein (TBP) antibodies were purchased
from Boster Biological Technology (PA1534). Histone H3 antibodies were purchased
from Thermo Fisher (PA5-16183). To deplete histones from NPE, two rounds of
depletion were performed by incubating 10 µL of extract with Protein-A Sepharose
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beads (GE Healthcare) bound to 50 µg of purified Histone H4 K12Ac antibodies(81) for 1
hour at 4°C.

RNA Sequencing Analysis
RNA was isolated from extract using the EZNA RNA Purification kit (OMEGA). Total
RNA samples were then analyzed by Novogene after rRNA removal using paired-end
RNA sequencing. A total of ~10,000,000 clean reads were obtained for both the pActin
and ΔPromoter plasmids. Output FASTQ files were aligned to the pActin sequence using
bowtie version 2.3.5(82). One nucleotide was removed from the 3’ and 5’ end of reads
and the subseeding length was 20. Bam files were sorted by samtools(83) and output
alignments were analyzed using Integrative Genomics Viewer.

2.3 Results
2.3.a Nucleoplasmic extract supports robust transcription of plasmid DNA
To determine the relative efficiency of transcription in NPE, we compared its
activity with other Xenopus egg extracts shown to have limited transcriptional activity,
including HSS (a high-speed supernatant of interphase-arrested eggs) and CSF (a
mitotic extract from eggs arrested in metaphase II by a “cytostatic factor”). Each extract
was incubated with increasing concentrations of a GFP reporter plasmid that contains a
Cytomegalovirus (CMV) promoter (Figure 2.1A; pCMV). The CMV promoter was
previously shown to support transcription in Xenopus oocytes(70) and cultured somatic
cell lysate(84), indicating that it is recognized by Xenopus transcription machinery.
Extracts were supplemented with [α-32P] UTP and its incorporation into RNA transcripts
was visualized by agarose gel electrophoresis and autoradiography (Figure 2.1B). When
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Figure 2.1. Nucleoplasmic extract (NPE) supports robust transcription of plasmid substrates. (A) pCMV
schematic. Relative location of promoter and GFP are indicated. (B) Different concentrations of pCMV were
incubated in NPE, HSS, or CSF extract in the presence of [α-32P] UTP. Samples were withdrawn at 180
minutes, resolved by agarose gel electrophoresis, and visualized by autoradiography. (C) Total UTP
incorporation from (B) was quantified and graphed. (D) pActin schematic showing the 5’ and 3’ regions cloned
from Xenopus actb. (E) pActin was incubated in NPE, HSS, or CSF and UTP incorporation was analyzed in
parallel to (B) to allow a direct comparison. (F) Total UTP incorporation from (E) was quantified and graphed
relative to peak intensity in (B). (G) Total protein from each extract was resolved by SDS-polyacrylamide gel
electrophoresis and visualized with Coomassie stain or by Western blot using the indicated antibodies.
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pCMV was incubated in HSS or CSF, there was little or no UTP incorporation,
respectively (Figure 2.1B, lanes 8-13 and 15-20). In contrast, incubation in NPE led to a
large accumulation of radiolabeled product (Figure 2.1B, lanes 1-6), indicating that
transcription of plasmid DNA readily occurs in NPE.
To investigate transcription of a promoter native to the Xenopus genome, we
replaced the 5’ and 3’ regions of pCMV with those from the Xenopus laevis actb gene to
form pActin (Figure 2.1D). actb encodes β-Actin, one of three major actin isoforms found
in

vertebrates,

and

is

known

to

be

transcriptionally

activated

during

egg

development(85). pActin was incubated in NPE, HSS, and CSF extracts and UTP
incorporation was visualized as described above. As seen with pCMV, pActin was
readily transcribed in NPE, but showed little or no UTP incorporation in HSS or CSF
(Figure 2.1E). At the highest DNA concentration tested (100 ng/µL), pCMV and pActin
had similar levels of UTP incorporation (compare blue traces in Figure 2.1C and F).
However, at lower DNA concentrations, pActin produced relatively fewer products.
These results suggest that transcription from the actb promoter is suppressed in NPE
and that the effect can be alleviated with excess DNA.
To compare the relative levels of transcription machinery in each extract, equal
volumes of NPE, HSS, and CSF were analyzed by Western blot and Coomassie stain.
Although total protein levels were relatively similar in each extract, RNAPII was highly
enriched in NPE compared to HSS and CSF (Figure 2.1G). We also saw that the level of
histone H3 was enriched in NPE and HSS, compared to CSF. Together, these results
suggest that factors enriched in NPE are able to overcome the naturally suppressive
effects of histones to promote transcription.
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2.3.b Transcription is driven by regulated recruitment of RNAPII to the promoter
To quantify transcription originating from the actb promoter, RNA products were
isolated from NPE and analyzed by reverse transcription quantitative PCR (RT-qPCR).
RNA levels were measured using primers that amplify a region ~150 bp downstream of
the actb promoter region (Promoter) or ~2400 bp upstream (Control) (Figure 2.2A).
Primers were also used to amplify endogenous Xenopus 18S rRNA that is retained
during the preparation of NPE to serve as an internal control for RNA recovery between
different samples.
When pActin was incubated in NPE, transcription from the actb promoter
increased over time, peaking at ~60 minutes (Figure 2.2B, solid cyan trace). In
comparison, transcription of the control region was relatively low, reaching only ~5% of
that detected at the promoter (Figure 2.2B, dashed cyan trace). We then supplemented
NPE with α-amanitin, a highly selective inhibitor of RNAPII(86). In the presence of αamanitin, transcription from both the promoter and control regions was reduced to <1%
of that detected from the promoter in buffer-treated samples (Figure 2.2B, solid and
dashed orange traces), indicating that transcription at both sites is RNAPII-dependent.
We showed that total UTP incorporation was sensitive to the concentration of
pActin incubated in NPE (Figure 2.1E and F). To directly test how DNA concentration
affected transcription from the actb promoter, we incubated NPE with increasing
concentrations of pActin, and then analyzed the accumulation of RNA products by RTqPCR. For comparison, we also analyzed transcription from a pActin control plasmid that
contained a deletion of the RNAPII core promoter elements (ΔPromoter). Total
transcription from the actb promoter increased with pActin concentration up to 25 ng/µL,
and then plateaued (Figure 2.2C, cyan trace). At all concentrations tested, transcription
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from the actb promoter region was severely reduced with the ΔPromoter plasmid
compared to pActin (Figure 2.2C, orange trace), showing that NPE supports promoterdriven transcription. By calculating the amount of transcription per plasmid, we saw that
transcription efficiency peaked at 25 ng/µL and was severely reduced at both lower and
higher DNA concentrations (Figure 2.2D, cyan trace). Similar results were also seen
when a fixed amount of pActin was incubated with increasing amounts of a “carrier”
plasmid that has no sequence homology (Figure 2.2E), indicating that transcription
efficiency was determined by total DNA concentration and not the number of actb
promoters present in the reaction. Thus, at low DNA concentrations, transcription from
the actb promoter is suppressed in NPE. At high DNA concentrations, the transcriptional
machinery likely becomes limiting, reducing overall efficiency but not total product
produced.
To verify that the actb promoter supports regulated transcription in NPE, we
analyzed recruitment of histone H3, RNAPII, and the transcription factor TATA-binding
protein (TBP) to the 5’ region of both the pActin and ΔPromoter plasmids by chromatin
immunoprecipitation (ChIP). Compared to pActin, binding of RNAPII and TBP to the
ΔPromoter plasmid was severely reduced (Figure 2.2F), consistent with the decrease in
transcription at the promoter region (Figure 2.2G). In contrast, histone H3 levels
remained similar for both plasmids. These results indicate that the actb promoter
supports sequence-specific recruitment of bona fide transcription factors to initiate
transcription in NPE. Notably, increasing the concentration of NPE in reactions greatly
increased the amount and rate of transcription (Figure 2.2H). However, the general
mechanisms of transcription regulation, such as promoter recognition and RNAPII
recruitment, remained consistent regardless of NPE concentration (data not shown).
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2.3.c Regulation of transcriptional activity by histone density
During early development, relative histone levels play an important role in
regulating the onset of transcription during the MBT. When plasmid DNA is incubated in
NPE, it becomes spontaneously chromatinized within ~30 minutes (Figure 2.3A). To
investigate whether the level of histone binding in NPE was responsible for decreased
transcription at low DNA concentrations, we first incubated different amounts of pActin in
NPE for 30 minutes and then analyzed DNA-bound histone H3 by ChIP. With increasing
concentrations of pActin, the recovery of histone-bound DNA was reduced by more than
10-fold (Figure 2.3B), indicating a dramatic decrease in the number of histones bound to
each plasmid.
We then tested whether plasmid concentration also affected DNA accessibility.
pActin was again incubated in NPE at various concentrations. After 60 minutes,
reactions were supplemented with Micrococcal Nuclease (MNase), which exhibits both
exo- and endonuclease activity against exposed double-stranded DNA. Reaction
samples containing equal amounts of DNA were withdrawn at different times after
MNase addition, separated by agarose gel electrophoresis, and then visualized with
SYBR Gold stain. As the concentration of pActin incubated in NPE increased, we saw
that its sensitivity to MNase digestion also increased (Figure 2.3C and D). Together,
these results suggest that changes in DNA concentration affect DNA accessibility by
altering histone density.
To determine whether histone availability controls the access of transcription
machinery to DNA, we immunodepleted NPE using pre-immune (Mock) or anti-histone
H4K12ac (ΔH) antibodies, which co-depleted more than 75% of total histone H3 from
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extract (Figure 2.3E)(81). pActin was then incubated in each extract, and samples were
withdrawn after 30 minutes to measure protein binding by ChIP. Compared to mockdepleted reactions, histone depletion reduced the level of DNA-bound histones by ~3fold (Figure 2.3F). In contrast, histone depletion caused TBP binding to increase ~2-fold,
consistent with greater access to nucleosome-free DNA. Although RNAPII levels were
not significantly changed, transcription also increased ~2-fold in histone-depleted
reactions (Figure 2.3G), suggesting that a greater fraction of DNA-associated RNAPII
complexes were activated by TBP and able to transcribe downstream from the promoter.
Together, these results suggest that reduced histone abundance allows increased
transcription factor binding and stimulates RNAPII activity, consistent with models
developed for Xenopus development(71-73).

2.3.d Transcription elongation and pre-mRNA processing in NPE
To further investigate how NPE supports transcription of the actb promoter, RNA
products were analyzed by RNA sequencing (RNA-Seq). pActin or the ΔPromoter
plasmid were each incubated in NPE at 25 ng/µL for 120 minutes. Total RNA was then
isolated and analyzed using paired-end RNA-Seq. RNA reads were aligned to the pActin
sequence and both forward (+) and reverse (-) reads were graphed. Consistent with RTqPCR results (Figure 2.2C), pActin showed a large accumulation of RNA immediately
downstream of the actb promoter in the forward orientation (Figure 2.4A, closed
arrowhead). A smaller RNA peak was also present upstream of the actb promoter in the
reverse orientation (Figure 2.4A, open arrowhead). This pattern of divergent transcription
from a promoter is thought to be important for maintaining a nucleosome-free region for
initiation and has been observed in organisms ranging from yeast to mammals(87). Both

29

ColE1 Origin

AmpR (bla)

5’ (actb)

GFP

3’ (actb)

Intron

ΔPromoter

A

Reads

1200000

500
501

1

1000
1001

1500
1501

2000
2001

2500
2501

3000
3001

3500
3501

4000
4001

4500
4501

4946 bp

pActin - Forward
pActin - Reverse

800000
400000
0
-400000

B

Reads

1200000

1

501

1001

1501

2001

2501

3001

3501

4001

4501

ΔPromoter - Forward
ΔPromoter - Reverse

800000
400000
0
-400000

C

1

501

1001

1501

2001

2501

3001

3501

Reads

1200000

4001

4501

pActin - Forward
pActin - Reverse
ΔPromoter - Forward
ΔPromoter - Reverse

800000
400000
0
-400000

E

Downstream
Transcription
(% of Promoter Signal)

Elongation
70
60
50
40
30
20
10
0
0

5

10

15

20

pActin (ng/µL)

25

Elongation

Downstream
Transcription
(% of Promoter Signal)

D

120

pCMV

100
80

pActin

60
40

pE-Actin

20
0
0

5

10

15

20

25

pDNA Concentration (ng/ul)

Figure 2.4. Analysis of whole-plasmid transcription in NPE. (A) pActin was incubated at 25 ng/µL in NPE for
120 minutes. RNA was then purified and analyzed by paired-end RNA sequencing. The total of all mapped reads
were graphed for both the forward (+) and reverse (−) orientations. (B) The ΔPromoter plasmid was incubated in
NPE and analyzed by RNA-seq as described in (A). (C) Reads from (A) and (B) were overlaid onto the same
graph for direct comparison. A diagram of pActin showing the relative position of major sequence elements is
shown above. See text for description of arrowheads. (D) pActin was incubated in NPE at the indicated
concentrations for 120 minutes. RNA was then isolated and analyzed by RT-qPCR to determine the efficiency of
elongation. Elongation was graphed as a percentage of amplification with Elongation primers versus Promoter
primers. (E) pActin, pE-Actin or pCMV was incubated in NPE for 120 minutes. RNA was isolated and analyzed by
RT-qPCR to determine elongation efficiency. Error bars represent +/- one standard deviation.

30

divergent peaks were completely absent in the ΔPromoter reads (Figure 2.4B),
indicating that formation of both RNA products was dependent on the actb promoter.
There were three major regions of actb-independent transcription found on pActin. The
largest peak was localized to the ColE1 origin (Figure 2.4B, closed arrowhead) and was
adjacent to a smaller peak in the opposite orientation (Figure 2.4B, open arrowhead).
These reads were likely produced by divergent transcription originating from an A/T-rich
region within the origin sequence(88). The third peak originated within the 5’ actb intron
(Figure 2.4B, gray arrowhead) and faced toward the major actb promoter peak. In a
previous study analyzing actb expression, deletion analysis identified a negative
transcriptional element in this region(89). Together with our RNA-Seq data, these results
suggest that the intron promoter may interfere with expression of actb(90). Interestingly,
transcription from both the ColE1 origin and the actb intron regions increased in the
ΔPromoter plasmid relative to pActin (Figure 2.4C, compare cyan with orange and blue
with red traces), suggesting that the actb promoter competes with nearby promoters.
We noted that forward transcription from the actb promoter was limited in length.
Transcripts showed highly efficient initiation and extension to ~250 nucleotides, well
beyond the short transcripts associated with abortive transcription (up to ~15
nucleotides)(91, 92). Roughly 16% of established transcripts escaped the promoter
region, extending further to ~310 nucleotides. Extension beyond this point failed rapidly,
with the vast majority of transcripts terminating by ~500 nucleotides. This phenomenon
was not specific to the actb promoter, as forward transcription from the ColE1 origin
(Figure 2.4B, closed arrowhead) and reverse transcription from the intron region (Figure
2.4B, gray arrowhead) also showed similar lengths of elongation.
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We reasoned that some factors involved in transcription elongation might be
limiting in extract. To test this hypothesis, pActin was incubated in NPE at different
concentrations for 120 minutes, and then RT-qPCR was used to measure transcription
at the promoter and another site ~600 bp downstream. Because total transcription levels
vary with plasmid concentration (as seen in Figure 2.2C), we graphed “elongation” as
the percentage of transcripts measured downstream versus at the promoter (Figure
2.4D). At 25 ng/µL, elongation efficiency was ~11%. However, with decreasing pActin
concentration, the efficiency of elongation increased dramatically, reaching ~56% at 1
ng/µL. Thus, transcription elongation improved at lower DNA concentrations in NPE,
despite higher levels of histone binding (Figure 2.3B). To test elongation on a separate
promoter, we used a similar approach for pCMV. Primers were designed equidistant to
the CMV promoter compared to pActin, and elongation was measured as described
above. Surprisingly, pCMV had much higher rates of elongation compared to pActin
(Figure 2.4E). The difference in elongation was not due to the enhancer sequence found
on pCMV, as when this sequence was cloned upstream of the actb promoter we
observed little to no change in elongation efficiency (Figure 2.4E; “pE-Actin”). Therefore,
this suggests that elongation in NPE may be promoter-dependent, and “stronger”
promoters, such as CMV, may bypass potential regulation that impedes endogenous
promoters.
The 5’ region of actb contains an intron that is typically spliced during expression
of the actb gene. However, analysis of the pActin RNA-Seq identified only a trace
amount of reads corresponding to spliced products (data not shown). To test whether
splicing improved with increased transcription elongation, RNA produced at different
pActin concentrations was analyzed by RT-qPCR using primers that amplify either
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unspliced or spliced transcripts (Figure 2.5B and C). As with elongation, splicing
efficiency increased when the concentration of pActin was reduced from 25 to 1 ng/µL
(Figure 2.5D), suggesting that the two processes are linked during transcription in
NPE(93).
To examine 3’ cleavage and polyadenylation, we first used an unbiased
approach to identify potential cleavage sites. pActin was incubated in NPE at 5 ng/µL for
120 minutes and RNA was isolated to generate cDNA. Transcripts were then amplified
using a forward primer that hybridizes upstream of the consensus polyadenylation
sequence(94) and an anchored oligo-dT reverse primer. The major PCR product was
gel-purified and sequenced. New primers were then designed that amplify either
uncleaved transcripts or those that have been cleaved and polyadenylated (Figure 2.5E
and F). RNA produced at different pActin concentrations was then analyzed to measure
the efficiency of cleavage and polyadenylation at this site. Unlike elongation and splicing,
the efficiency of cleavage and polyadenylation remained relatively constant at each
pActin concentration tested (Figure 2.5G). Taken together, these results indicate that
NPE supports regulated transcription from native promoters and subsequent pre-mRNA
processing required to generate mature mRNA transcripts.

2.4 Discussion
Xenopus egg extracts have been used extensively to study numerous biological
processes in a highly tractable system. A major advantage of extracts over cell-based
models is the ability to study direct effects in the absence of global gene expression and
cell cycle changes. However, traditional Xenopus egg extracts have been found to
support only limited transcription without the addition of exogenous transcription
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Figure 2.5. pre-mRNA processing in NPE. (A) pActin schematic showing the relative positions of Unspliced,
Spliced, Uncleaved, and Cleaved and Polyadenylated primer pairs. (B-C) The specificity of each primer pair was
analyzed by qPCR with the corresponding unprocessed and processed DNA templates. “Background”
amplification of the incorrect DNA template was graphed as a percentage of total amplification measured with the
correct DNA template. (D) pActin was incubated in NPE at the indicated concentrations for 120 minutes. RNA was
then isolated and analyzed by RT-qPCR to determine the efficiency of splicing. (E-F) The specificity of each primer
pair was analyzed by qPCR with the corresponding unprocessed and processed DNA templates. “Background”
amplification of the incorrect DNA template was graphed as a percentage of total amplification measured with the
correct DNA template. (G) pActin was incubated in NPE at the indicated concentrations for 120 minutes. RNA was
then isolated and analyzed by RT-qPCR to determine the efficiency of polyadenylation. Splicing and cleavage and
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respectively. Error bars represent +/- one standard deviation.
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machinery or the removal of endogenous histones to prevent DNA chromatinization(7073). In this study, we establish a new cell-free system using NPE that supports robust
transcription of chromatinized substrates by endogenous factors.
NPE contains a highly concentrated fraction of soluble, nuclear proteins. Relative
to other Xenopus egg extracts, NPE is enriched for both transcription machinery and
histones (Figure 2.1G). This combination of factors supports robust transcription (Figure
2.1B and E) in the context of chromatinized DNA (Figures 2.3A). NPE is prepared from
nuclei undergoing active DNA synthesis. As such, transcription in NPE likely resembles
that of cells within S phase. Although the primary mechanics of transcription are similar
throughout the cell cycle, the regulation of specific genes and transcription factors may
be influenced by these characteristics of NPE.
Xenopus eggs contain an abundance of histone dimers/tetramers that are
coupled to molecular chaperones(95, 96). In NPE, these complexes promote
spontaneous loading of histones onto DNA within ~30 minutes (Figure 2.3A). Although
transcription of pActin begins prior to complete chromatinization, robust transcription
continues up to ~60 minutes before leveling off (Figure 2.2B). The decline in
transcription activity over time is not due to limited availability of ribonucleotides or ATP
(data not shown). This limited window of transcription suggests that factors required for
initiating transcription become inactivated or suppressed over time, possibly due to
changes in chromatin signaling(6).
Based on the final quantity of RNA detected by qPCR and the efficiencies of
RNA isolation and cDNA amplification (determined using samples of known
concentration), we estimate that the actb promoter produced ~2.5 extended transcripts
per molecule of pActin when incubated in NPE. Transcriptional efficiency of the actb
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promoter peaked at 25 ng/µL (Figure 2.2D and E), suggesting a balance between fully
chromatinized DNA that suppresses transcription and under-chromatinized DNA that
supports increased transcription factor binding (Figure 2.3F). These conditions are likely
analogous to the cellular states of chromatin referred to as heterochromatin and
euchromatin, respectively(97).
During early embryo development, histones act as a sensor for the number of
cellular divisions. As histones become limiting, it triggers the MBT, which marks the
onset of transcription and developmental progression(3, 71, 72). In NPE, the ratio of
DNA to extract plays a similar role in regulating transcription, which can be modulated by
altering the concentration of plasmid present within the reaction (Figure 2.2C). Previous
studies have shown that the MBT can be altered by adding or depleting histones(71, 72),
arguing that histone levels control the onset of transcription. Our results indicate that
transcription in NPE is regulated by the same mechanism. Increasing plasmid DNA
concentration reduced histone binding (Figure 2.3B) and increased DNA accessibility
(Figure 2.3C and D). We also showed that histone binding limited recruitment of TBP to
the actb promoter (Figure 2.3F), adding support to the model that histone occupancy
suppresses transcription by obscuring genes during early embryo development.
Using RNA Seq, we performed a detailed analysis of transcripts produced by
pActin and the ΔPromoter plasmids. We saw traditional patterns of divergent
transcription originating from the actb promoter and plasmid origin sequence (Figure
2.4A). Promoters that support divergent transcription initiate bi-directional transcripts
read from opposite DNA strands. Although some anti-sense transcripts are unstable and
quickly degraded, others have important regulatory functions(98). Despite the
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prevalence of divergent transcription throughout higher order species, the mechanism of
its regulation and biological purpose remain poorly understood.
Within the 5’ intron of actb, we identified a putative promoter (Figure 2.4B, gray
arrowhead) oriented toward the actb promoter (Figure 2.4A, closed arrowhead).
Transcription from the intron promoter was weaker than that of actb, but increased when
the core promoter elements of actb were deleted (Figure 2.4C). Although this region of
actb was proposed to contain a negative regulatory element(89), its potential role in
regulating gene expression has not been explored. Notably, the intrinsic activity of weak
or dormant promoters may also be elevated in this system due to the absence of other
genomic elements that normally compete for access to limited transcription factors and
machinery.
Interestingly, we found that pre-mRNA processing events responded differently
to changes in plasmid concentration. The efficiency of cleavage and polyadenylation
remained relatively constant at different plasmid concentrations (Figure 2.5G),
suggesting that the required factors are present in excess or able to function
independently of other transcriptional events. In contrast, the efficiency of transcription
elongation and splicing both improved in a non-linear fashion with decreasing pActin
concentration (Figures 2.4D and 2.5D), arguing that a threshold must be achieved for full
stimulation. Furthermore, the addition of an artificial enhancer sequence to the actb
promoter did not significantly improve elongation (Figure 2.4E). Therefore, we propose
that highly chromatinized DNA is required for efficient elongation and splicing to occur in
NPE. Although histones generally play a negative role in transcription initiation (Figure
2.3G), they are also critical for chromatin signaling that regulates many downstream
events(99-102).
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Together, the results described in this study add another fundamental process to
NPE’s repertoire. As such, it provides a unique tool to examine the interplay between
different cellular processes and the various pathways that regulate them. Decades of
research have revealed an array of dynamic regulatory networks that control each phase
of gene expression(99, 103, 104). When these mechanisms fail, it can result in the
development of numerous diseases, including cancer(102, 105-107). Understanding
how different signaling events directly impact the initial phases of gene expression will
provide new insight into the mechanisms of disease and identify new strategies for
treatment.
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Chapter 3: BRCA1-BARD1 regulates transcription through BRD4
in nucleoplasmic extract

Sections from Chapter 3 were previously published in Nucleic Acids Research, an
Oxford University Press journal, with permissions and contributions from authors John K.
Barrows, George Fullbright and David T. Long.

3.1 Premise
BRCA1 (breast cancer susceptibility protein 1) is an established tumor
suppressor that plays a critical role in the development of both sporadic and hereditary
breast and ovarian cancer(108). Considered a “master regulator” of genome integrity,
BRCA1 has been linked to nearly all aspects of chromatin biology(109). Loss of BRCA1
leads to widespread defects in DNA repair, cellular stress signaling, cell cycle
progression, apoptosis, chromatin condensation, and gene expression(110).
BRCA1’s different cellular activities are regulated by a variety of protein-protein
interactions

and

post-translational

modifications(109,

111).

BRCA1

forms

a

heterodimeric complex with BARD1 (BRCA1-associated RING domain protein 1). The
two proteins interact through their respective N-terminal RING domains to form an E3
ubiquitin ligase(29). Binding to BARD1 also masks a nuclear export signal (NES) on
BRCA1, thereby promoting nuclear retention and stability of the complex(112). BRCA1
contains a central coiled-coil domain that interacts with PALB2 (partner and localizer of
BRCA2) and BRCA2 (breast cancer susceptibility protein 2) to stimulate RAD51 loading
and homologous recombination(32). BRCA1 and BARD1 also contain tandem BRCT
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repeats in their C-termini that support interaction with phospho-proteins involved in
damage signaling and protein localization(113).
In addition to its established DNA repair functions, BRCA1 has been linked to
various mechanisms of transcription regulation(42). BRCA1 interacts with the RNA
polymerase II holoenzyme(114) through RNA helicase A(115), and with the negative
elongation factor (NELF) complex through COBRA1(50). BRCA1 also binds to various
transcription factors, including p53(116), c-MYC(117), ERα(118), GATA3(119), and
others. BRCA1 has been shown to play a role in chromatin decondensation through
interactions

with

SWI/SNF

remodeling

complexes(120-122)

and

the

histone

acetyltransferases P300 and CBP(123). Conversely, BRCA1 and BARD1 have been
linked to chromatin condensation through interactions with the DNA methyltransferase
DNMT3B and heterochromatin protein 1 (HP1)(124, 125). BRCA1-BARD1 can also
catalyze ubiqutination of histone H2A(44, 126), which is generally associated with
transcription repression(126, 127).
Despite extensive study, the context and functional role that BRCA1 plays in
transcription regulation remains poorly understood. We previously showed that
nucleoplasmic extract (NPE), prepared from Xenopus laevis eggs, readily promotes
chromatinization and transcription of plasmid-borne gene constructs(128). Using this
system, we sought to investigate BRCA1’s role as a transcription regulator.

3.2 Methods and Materials
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Construction of plasmid substrates
pActin was generated as described previously(128). pCMV was purchased from
Addgene (#11153). To create pBRCA1, the 5’ and 3’ regions of Xenopus laevis BRCA1
were amplified from sperm chromatin with the following primer pairs:

5’ region:

GCGCTGCCTAGGCCTGGGGCCAACATTTTTTTTTTAACTT and
TAGACCATGGTGGCTTGTCCTTTAGATAATACATTGGTTAAATGCAAT

3’ region:

ATAGCGGCCGCAATCACAGTGGAACTGGCCGGTTA and
CAGGAACTAGTCATCATTTAGAGAATCAACCTATCCAGCCTCAGA

The resulting fragments were then cloned into pCMV using AvrII and NcoI (5’ region), or
NotI and SpeI (3’ region). pCON was generated as described previously(76), and
digested with BbsI to create pDSB. For pCarrier, the pFastBac1-BARD1 vector was
used(79).

Incubations in Xenopus egg extracts
NPE was prepared as described previously(9). All reactions were supplemented with an
ATP regeneration mix (6.5 mM phosphocreatine, 0.65 mM ATP, and 1.6 µg/mL creatine
phosphokinase) and 1 mM DTT. All incubations were performed at 21°C. Extracts were
placed at 21°C for 10 minutes prior to the addition of 2.5-10 ng/µL plasmid DNA, which
represents the reaction start time. Where indicated, reactions were supplemented with 5
ng/uL pCON or pDSB, 5 mM caffeine (Fisher), 10-100 µM VE-821 (Abcam), 10-100 µM
KU-5593 (Abcam), 20 µM ubiquitin vinyl sulfone (Fisher), 30 µM JQ1 (Sigma), 100 µM
SAHA (Cayman Chemical), 0.5 mM Abraxas peptides, 60 µM SGC-CBP30 (Sigma) or
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40-400 nM recombinant BRCA1-BARD1. The endogenous level of BRCA1-BARD1 in
NPE is estimated to be ~40 nM. All reactions were performed at least two times with
representative or averaged data shown. Where indicated, data were graphed with error
bars representing +/- 1 standard deviation and p values determined using a two-tailed ttest: p<0.05 (*), p<0.005 (**), p<0.0005 (***), p≥0.05 (not significant; n.s.).

Reverse transcription quantitative PCR (RT-qPCR)
RNA was isolated from extract using the EZNA RNA Purification kit (Omega Bio-tek).
cDNA was produced using QuantiTect Reverse Transcription kit (Qiagen) and then
analyzed by quantitative PCR. cDNA generated by gene constructs was normalized to
endogenous 18S rRNA to correct for differences in column recovery between time points
and conditions. Unless indicated, data are graphed from amplification with the pActin
(+10 to +153) primers. The following primer pairs were used:

pActin:

(+10 to +153) CCCGCATAGAAAGGAGACA and
GCCAGAACATAGACATTAAGAAGG;
(+174 to +289): TGAAATGGCCATGACTTGAG and
GCAGTGCCCTGTAACAATGA;
(+599 to +716): GCGCTTTACGTTAGCAATCC and
AGGCTTTCAGTGAGCCAGTC

pBRCA1:

CAACCTTTAGGTCTATTTCAACCCA and
CCACCTTTAGGTCTATTTCAACCCA

pCMV:

AGCTGGACGGCGACGTAAAC and AGGTCAGGGTGGTCACGAGG

18S rRNA: GACCGGCGCAAGACGAACCA and TGCTCGGCGGGTCATGGGAA
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Antibodies and immunodepletion
RNA polymerase II and BRG1 antibodies were obtained from Bethyl Laboratories (A304405A and A300-813A, respectively). TATA-binding protein (TBP) antibodies were
obtained from Boster Biological Technology (PA1534). Histone H3 antibodies were
obtained from Thermo Fisher (PA5-16183). Phospho-Chk1 (Ser345) and ubiquitin
(P4D1) antibodies were obtained from Cell Signaling (#2341 and #3936, respectively).
Ubiquityl-histone H2A antibodies were obtained from Millipore (05-678). Histone H4
acetyl-K5, K8 and K16 antibodies were obtained from Abclonal (A15233, A7258, and
A5280, respectively). Histone H4 acetyl-K12 antibodies were gifted by Dr. Hiroshi
Kimura (Tokyo Institute of Technology, Tokyo, Japan)(81). Xenopus BRCA1 and BARD1
antibodies were generated by New England Peptide. BRD4 antibodies were provided by
Dr. Igor Dawid, NIH/NICHD(129). For depletion experiments, 10 µL of NPE was
incubated with 4 µL of Protein-A Sepharose Fast Flow beads (GE Healthcare) that were
pre-bound with either 16 µL of pre-immune (mock) or αBRCA1 serum for 1 hour at 4°C.
After three rounds of depletion, the resulting mock- and BRCA1-depleted extracts were
immediately used for experiments. BRD4 depletions were performed similarly, but for
only two rounds. For rescue experiments, recombinant full-length BRD4 was purchased
from Reaction Biology (#RD-21-153).

Purification of recombinant BRCA1-BARD1
The full-length Xenopus laevis BRCA1-BARD1 heterodimer was purified as previously
described(79). Briefly, Sf9 cells were co-infected with recombinant baculoviruses
containing FLAG-BRCA1 and HA-BARD1, or FLAG-BRCA1I26A and HA-BARD1. The
resulting heterodimers were isolated by sequential affinity chromatography using anti-
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FLAG M2 agarose (Sigma, A2220) and anti-HA agarose (Sigma, A2095). We used sitedirected mutagenesis (Agilent, 210518) to create the BRCA1I26A mutant from the parent
FLAG-BRCA1 pFastBac vector using the following primers:

Forward:

CTTCATCAGCTCTAAGCAGGCTGGGCACTCCAAATTCTTC

Reverse:

GAAGAATTTGGAGTGCCCAGCCTGCTTAGAGCTGATGAAG

Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously(130). Briefly, reaction samples were
crosslinked in Egg Lysis Buffer (ELB: 10 mM HEPES-KOH pH 7.7, 50 mM KCl, 2.5 mM
MgCl2, and 250 mM sucrose) containing 1% formaldehyde. Crosslinking was stopped
with the addition of 125 mM glycine and then excess formaldehyde was removed with a
Micro Bio-Spin 6 chromatography column (Bio-Rad). Samples were sonicated
(Diagenode Bioruptor UCD-600 TS) and immunoprecipitated with the indicated
antibodies. Crosslinks were then reversed, and the resulting DNA was isolated by
phenol/chloroform extraction and ethanol precipitation. qPCR was then used to quantify
recovered DNA as a fraction of total DNA (INPUT) and graphed. The following primers
were used:

pActin:

(“PRO” -120 to +71) CCTCCTTCGTCCGCAGTTCC and
GCTGGCGAACCGCTACTTGC
(“FAR”

+2248

to +2432) CCCAACCAGTGTTACACCACTTCC

and

ATGCCTGGGAGCGGCCTTAT
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Plasmid pull-down
Plasmids were isolated from extract as described previously(80). Briefly, reaction
samples were added to LacI-coupled magnetic beads (Dynabeads M-280; Invitrogen)
suspended in LacI pull-down buffer (10 mM HEPES pH 7.7, 2.5 mM MgCl2, 50 mM KCl,
250 mM sucrose, 0.25 mg/mL BSA, and 0.02% Tween 20). Samples were then rotated
at 4°C for 20 minutes, washed three times with LacI wash buffer (10 mM HEPES pH 7.7,
2.5 mM MgCl2, 50 mM KCl, 0.25 mg/mL BSA, and 0.02% Tween 20), dried, and
suspended in 2x SDS sample buffer (100 mM Tris-HCl pH 6.8, 4% SDS, 0.2%
bromophenol blue, 20% glycerol, and 200 mM β-mercaptoethanol). The resulting DNAbound proteins were then resolved by SDS-PAGE, and visualized by Western blotting
with the indicated antibodies. To visualize recovered DNA, pull-down samples were
treated with 2 µg RNase at 37°C for 30 minutes, and then incubated with 20 µg
proteinase K at 21°C for 16 hours. DNA was resolved by agarose gel electrophoresis
and visualized with SYBR Gold stain (Thermo Scientific).

Nuclease Digestion
Plasmid DNA was incubated in NPE at 20 ng/µL for 30 minutes. Reactions samples
were then diluted 100-fold in Digestion Buffer (50 mM Tris-HCl pH 7.9, and 5 mM CaCl2)
containing 1,500 U/mL MNase (New England Biolabs). Digestion reactions were stopped
at the indicated time points with 1/8th volume of Digestion Stop Solution (160 mM EDTA,
6.8% SDS). Samples were then incubated with 60 µg Proteinase K overnight at 21°C.
DNA was isolated by phenol/chloroform extraction and ethanol precipitation. Resulting
DNA intermediates were resolved on a 1.5% agarose gel and visualized with SYBR Gold
stain.
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Chromatin decondensation assay
NPE was incubated with 1,250 demembranated sperm chromatin per µL at 21°C. At the
indicated time points, samples were withdrawn from the reaction and visualized by
phase contrast light microscopy. Chromatin volume and density were determined by
quantifying two-dimensional area and average visual opacity of individual sperm
chromatin, respectively.

In vitro ubiquitination assay
Reactions containing 2 mM ATP, 12 µM ubiquitin, 250 nM UBE1 (R&D Systems), 1.75
µM UBE2D1 (R&D Systems), and 17 nM of Xenopus laevis BRCA1-BARD1 or
BRCA1I26A-BARD1 were incubated for 30 min at 37°C. For control reactions, either
ubiquitin or BRCA1-BARD1 was omitted. Reactions were stopped with 2x SDS sample
buffer, resolved by SDS-PAGE, and visualized by Western blotting with the indicated
antibodies.

Mass spectrometry analysis
DNA-bound proteins were isolated by plasmid pull-down, resolved briefly by SDS-PAGE,
stained with Coomassie Brilliant Blue, and then excised. The gel fragments were sent to
the Taplin Mass Spectrometry Facility (Harvard Medical School, Boston, MA) for
processing and analysis. The average sum intensity of proteins isolated above
background (-DNA samples) was determined for each condition and quantified for
enrichment over mock-depleted reactions (ΔMock). Proteins were ranked for enrichment
in ΔBRCA1 reactions over +BRCA1-BARD1 reactions. Thus, a “high” score represents
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proteins whose DNA binding was enriched in the absence of BRCA1 and reduced in the
presence of elevated BRCA1-BARD1, and a “low” score represents proteins whose DNA
binding was lost in the absence of BRCA1 and increased in the presence of elevated
BRCA1-BARD1.

3.3 Results
3.3.a BRCA1-BARD1 is necessary and sufficient to suppress transcription in NPE
A plasmid containing the 5’ and 3’ elements of the actb gene (pActin; Figure
2.1D) was incubated in NPE that was immunodepleted with pre-immune (mock) or
BRCA1 antibodies (Figure 3.1A) and formation of RNA was analyzed by reverse
transcription quantitative PCR (RT-qPCR). In the absence of BRCA1, both the rate and
duration of transcription activity increased compared to mock-depleted reactions (Figure
3.1B). Similar results were observed using different gene constructs (Figure 3.1C-F),
suggesting that BRCA1 suppressed transcription through a broad or sequenceindependent mechanism. To confirm that the depletion effects were specifically due to
removal of BRCA1-BARD1, we purified the full-length complex by tandem affinity pulldown (Figure 3.1G). When recombinant BRCA1-BARD1 was added to BRCA1-depleted
extract, we saw that transcription activity was suppressed compared to both mock- and
BRCA1-depleted reactions (Figure 3.1H). Recombinant BRCA1-BARD1 was also able to
suppress transcription of undepleted extract in a dose-dependent manner (Figure 3.1I).
Taken together, these results indicate that BRCA1-BARD1 is both necessary and
sufficient to suppress a critical step during transcription in NPE.
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Figure 3.1. BRCA1-BARD1 is necessary and sufficient to suppress transcription in NPE. (A) Different
amounts of Mock-depleted (ΔMock) or BRCA1-depleted (ΔBRCA1) NPE was analyzed by Western blot with the
indicated antibodies. (B) pActin was incubated in mock- or BRCA1-depleted extract and RNA was quantified by RTqPCR over time (n=3). (C) Schematic of pBRCA1. (D) pBRCA1 was incubated in mock- or BRCA1-depleted extract
for 120 minutes and RNA was analyzed by RT-qPCR (n=3). (E) Schematic of pCMV. (F) pCMV was incubated in
mock- or BRCA1-depleted extract for 120 minutes and RNA was analyzed by RT-qPCR (n=3). (G) Purified BRCA1BARD1 (WT) and BRCA1I26A-BARD1 (I26A; used in Figure 4E) were resolved by SDS-PAGE and visualized by
silver stain. (H) pActin was incubated in mock-depleted extract, BRCA1-depleted extract, or BRCA1-depleted
extract supplemented with recombinant 200 nM BRCA1-BARD1. After 120 minutes, RNA was quantified by RTqPCR (n=2) (I) pActin was incubated in NPE supplemented with increasing amounts of BRCA1-BARD1. After 120
minutes, RNA was quantified by RT-qPCR (n=3).
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3.3.b BRCA1 suppresses transcription independent of DNA damage signaling
BRCA1’s role in regulating gene expression has typically been described in the
context of a DNA damage response(131-133). To test whether damage signaling is
required for BRCA1-mediated transcription suppression, we supplemented mock- or
BRCA1-depleted extract with caffeine, a broad kinase inhibitor that targets both ATM
and ATR(134). In the presence of caffeine, phosphorylation of the checkpoint kinase
Chk1 was completely blocked (Figure 3.2A), indicating general disruption of damage
signaling. In both mock- and BRCA1-depleted reactions, caffeine reduced transcription
activity ~5-fold compared to a buffer control (Figure 3.2B). However, caffeine did not
affect the relative increase in transcription caused by BRCA1 depletion (5.4- vs. 4.1fold), indicating that the extent of BRCA1-mediated suppression was unchanged. Similar
effects were also seen in reactions supplemented with the ATR inhibitor VE-821 or the
ATM inhibitor KU-5593. Both inhibitors were able to reduce Chk1 phosphorylation
(Figure 3.2C), but did not limit the increased transcription associated with BRCA1 loss
(Figure 3.2D).
We also tested whether exogenous DNA damage would affect BRCA1-mediated
transcription suppression. Mock- or BRCA1-depleted reactions were supplemented with
a second plasmid that was undamaged (pCON) or had been digested to create a
double-strand break (pDSB). Chk1 phosphorylation was elevated in reactions
supplemented with pDSB compared to pCON (Figure 3.2E), indicating induction of a
DNA damage response. In both mock- and BRCA1-depleted reactions, pDSB increased
transcription activity ~2.7-fold compared to the pCON reactions (Figure 3.2F). However,
the relative increase in transcription caused by BRCA1 depletion was again similar (2.0vs. 1.8-fold). Notably, BRCA1 depletion itself did not affect the topology or integrity of
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Figure 3.1. BRCA1-BARD1 is necessary and sufficient to suppress transcription in NPE. (A) Different
amounts of Mock-depleted (ΔMock) or BRCA1-depleted (ΔBRCA1) NPE was analyzed by Western blot with the
indicated antibodies. (B) pActin was incubated in mock- or BRCA1-depleted extract and RNA was quantified by RTqPCR over time (n=3). (C) Schematic of pBRCA1. (D) pBRCA1 was incubated in mock- or BRCA1-depleted extract
for 120 minutes and RNA was analyzed by RT-qPCR (n=3). (E) Schematic of pCMV. (F) pCMV was incubated in
mock- or BRCA1-depleted extract for 120 minutes and RNA was analyzed by RT-qPCR (n=3). (G) Purified BRCA1BARD1 (WT) and BRCA1I26A-BARD1 (I26A; used in Figure 4E) were resolved by SDS-PAGE and visualized by
silver stain. (H) pActin was incubated in mock-depleted extract, BRCA1-depleted extract, or BRCA1-depleted
extract supplemented with recombinant 200 nM BRCA1-BARD1. After 120 minutes, RNA was quantified by RTqPCR (n=2) (I) pActin was incubated in NPE supplemented with increasing amounts of BRCA1-BARD1. After 120
minutes, RNA was quantified by RT-qPCR (n=3).
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plasmid DNA incubated in extract (Figure 3.2G). Altogether, these results indicate that
BRCA1 suppresses transcription independent of DNA damage signaling.

3.3.c Transcription suppression involves a histone intermediate
In the embryos of rapidly developing species, transcription activity is regulated by
the density of maternally-supplied histones(71, 73). We previously showed that a similar
mechanism also controls transcription in NPE(128), which supports nucleosome
formation (Figure 3.3A)(135). To test whether BRCA1’s ability to suppress transcription
was linked to histone density, we compared transcription in mock- and BRCA1-depleted
extracts incubated with 2.5 ng/uL pActin and increasing concentrations of a “carrier”
plasmid with no sequence homology. At lower DNA concentrations (when histone
density is high), BRCA1 depletion increased transcription ~9-fold (Figure 3.3B). At higher
DNA concentrations (when histone density is low), transcription in BRCA1-depleted
reactions was at or below the level found in mock-depleted reactions. Thus, BRCA1mediated suppression is lost under conditions that support low histone density, arguing
that BRCA1 functions through a histone intermediate.
To investigate how BRCA1 suppresses transcription, DNA-bound proteins were
analyzed by chromatin immunoprecipitation (ChIP) using primers that amplify the actb
promoter region. We first tested whether histone binding was altered by analyzing DNAbound histone H3 in reactions with mock- or BRCA1-depleted extract (Figure 3.3C), or
reactions supplemented with buffer or recombinant BRCA1-BARD1 (Figure 3.3D). In
each reaction, the level of DNA-bound histone H3 showed little or no change, ruling out
the possibility that BRCA1 suppressed transcription by increasing histone density. We
also analyzed recruitment of the transcription factor TATA-Binding Protein (TBP; Figure
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Figure 3.3. BRCA1 regulates transcription initiation through a histone intermediate. (A) pActin was incubated
in extract for 30 minutes. Reaction samples were then withdrawn and digested with MNase for the indicated time.
DNA fragments were isolated and resolved by agarose gel electrophoresis. The predicted migration of mono-, di-,
and tri-nucleosome fragments is indicated. (B) 2.5 ng/µL pActin was incubated in mock- or BRCA1-depleted extract
with increasing amounts of carrier plasmid. After 120 minutes, RNA was quantified by RT-qPCR (n=2). For
comparison, values were normalized to ΔMock reactions at each concentration. (C) pActin was incubated in mockor BRCA1-depleted extract. Samples were withdrawn after 60 minutes and analyzed by ChIP with histone H3
antibodies (n=3). (D) pActin was incubated in extract supplemented with buffer or 200 nM BRCA1-BARD1. Samples
were withdrawn after 60 minutes and analyzed by ChIP with histone H3 antibodies (n=3). (E-F) TBP- and RNAPIIChIPs were performed as in (C) (n=3). (G-H) pActin was incubated in mock- or BRCA1-depleted extract. After 120
minutes, RNA was isolated and analyzed by RT-qPCR at different distances from the actb transcription start site
(TSS) (n=2). Relative total transcription for each reaction is shown in (G), and transcription normalized to the peak
value in each reaction is shown in (H). (I-K) Sperm chromatin was incubated in mock- or BRCA1-depleted extract.
At the indicated time points, samples were visualized by phase contrast light microscopy (I). Chromatin volume (J)
and density (K) were calculated at 150 minutes (n≥12).
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3.3E) and RNAPII (Figure 3.3F). Compared to mock-depleted reactions, DNA-binding of
both proteins increased in the absence of BRCA1. Although total transcription increased
in the absence of BRCA1 (Figure 3.3G), the relative efficiency of extension downstream
from the promoter was unchanged (Figure 3.3H). Together, these results support the
idea that BRCA1 functions upstream of transcription initiation by restricting access of
transcription factors to DNA. Consistent with this interpretation, we saw that BRCA1
depletion also increased the speed and extent of chromatin decondensation in NPE
(Figure 3.3I-K).

3.3.d Ubiquitin and E3 ligase activity are dispensable for transcription
suppression
BRCA1 has been implicated in multiple mechanisms of chromatin remodeling
that act upstream of transcription initiation(42). Of these, the best-characterized
mechanism involves ubiquitination of histone H2A (H2A-Ub). H2A-Ub mediated by
BRCA1-BARD1 has been linked to heterochromatin formation and transcription
suppression(126). To test whether BRCA1-BARD1 regulates formation of H2A-Ub in
extract, protein binding was analyzed by ChIP. We found that BRCA1 depletion led to a
mild decrease in H2A-Ub relative to total histone levels (Figure 3.4A). Conversely, the
addition of BRCA1-BARD1 to extract increased H2A-Ub ~3-fold compared to buffer
controls (Figure 3.4B). These results indicate that some ubiquitinated H2A is present in
extract and that its formation is potentially regulated by BRCA1-BARD1.
To investigate the role of ubiquitination in transcription suppression, we preincubated extract with ubiquitin vinyl sulfone (UbVS), an irreversible de-ubiquitinase
(DUB) inhibitor. In the presence of UbVS, ubiquitin turnover is blocked and free ubiquitin
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Figure 3.4. Ubiquitination is dispensable for BRCA1-mediated transcription suppression. (A) pActin was
incubated in mock- or BRCA1-depleted extract. Samples were withdrawn after 60 minutes and analyzed by ChIP
with histone H2A-Ub or H3 antibodies. Recovery of H2A-Ub over H3 is graphed (n=2). (B) pActin was incubated in
extract supplemented with buffer or 200 nM BRCA1-BARD1. Samples were analyzed by ChIP as in (A) (n=2). (C-D)
pActin was incubated in extract pre-treated with buffer or UbVS and then supplemented with buffer or 200 nM
BRCA1-BARD1. Samples were withdrawn after 60 minutes and analyzed by Western blot (C), or 120 minutes and
RNA was quantified by RT-qPCR (D) (n=2). (E-F) The ubiquitination activity of BRCA1-BARD1 (WT) or BRCA1I26ABARD1 (I26A) was tested in vitro (see Methods). After 30 minutes, reaction samples were analyzed by Western blot
with (E) ubiquitin, or (F) BRCA1 antibodies. Functional BRCA1-BARD1 promotes autoubiquitination of BRCA1,
which is aolished by the I26A mutation in BRCA1’s RING domain. (G) pActin was incubated in NPE supplemented
with increasing amounts of BRCA1I26A-BARD1. After 120 minutes, RNA was quantified by RT-qPCR (n=3). Results
from Figure 3.1I are also shown for comparison.
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is rapidly depleted from extract(136), thereby preventing additional ubiquitination events
(Figure 3.4C). Extracts treated with buffer or UbVS were then supplemented with buffer
or BRCA1-BARD1 and transcription was analyzed by RT-qPCR. Despite the absence of
free ubiquitin, BRCA1-BARD1 still suppressed transcription with the same efficiency as
buffer-treated reactions (Figure 3.4D). We then tested whether BRCA1-BARD1’s
ubiquitin ligase activity was required for transcription suppression. We generated a
mutant BRCA1-BARD1 complex containing an I26A substitution in BRCA1 (Figure
3.1G), which retains interaction between BRCA1-BARD1, but disrupts E2 binding
required for ubiquitin transfer(137) (Figure 3.4E-F). When the BRCA1I26A-BARD1
complex was added to extract, transcription was abolished in a dose-dependent manner,
demonstrating nearly identical activity to the wild-type complex (Figure 3.4G). Taken
together, these results indicate that ubiquitin and E3 ligase activity are dispensable for
transcription suppression by BRCA1-BARD1.

3.3.e BRCA1-BARD1 regulates DNA binding of the chromatin reader BRD4
To uncover alternative mechanisms of BRCA1-BARD1-mediated transcription
suppression, we analyzed DNA binding in extract that was mock-depleted, BRCA1depleted, or supplemented with BRCA1-BARD1. DNA-bound proteins were isolated by
plasmid pull-down and identified by mass spectrometry. Results were ranked for
enrichment in ΔBRCA1 over +BRCA1-BARD1 reactions to identify proteins whose DNA
binding was increased in the absence of BRCA1 and also reduced in the presence of
excess BRCA1-BARD1, or vice versa. Factors involved in DNA repair and chromatin
organization were highly represented throughout the data set (Figure 3.5A). As
expected, members of the BRCA1-BARD1 complex scored “low”, indicating that their
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the relationship between BRCA1, BRD4, and complexes identified in (B).
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DNA binding was positively regulated by the presence of BRCA1-BARD1. We also found
that four associated complexes involved in chromatin and transcription regulation
(SWI/SNF, Mediator, P-TEFb, and the Super Elongation Complex) scored “high”,
indicating that their DNA binding was negatively regulated by the presence of BRCA1BARD1 (Figure 3.5B). Recruitment of these complexes to chromatin is regulated by the
bromo- and extraterminal-domain (BET) protein BRD4 (Figure 3.5C), which also scored
high. BRD4 is an epigenetic reader that binds to acetylated histones and is widely
implicated in transcription activation(65). BRD4 is essential during embryogenesis(4)
and plays an important role in cell differentiation later in development(138, 139). BRD4
has also been shown to play a role in homologous recombination-mediated DNA
repair(66), although a functional link to BRCA1 has not been established.
To confirm whether BRCA1 regulates the recruitment of BRD4 to DNA, pActin
was incubated in mock- or BRCA1-depleted extract and DNA-bound proteins were
analyzed by plasmid pull-down. We saw that BRD4 was present on DNA in mockdepleted reactions and increased in the absence of BRCA1 (Figure 3.6A). DNA binding
of BRD4 was also analyzed in reactions supplemented with buffer or BRCA1-BARD1. In
the presence of excess BRCA1-BARD1, BRD4 binding to DNA was completely blocked
(Figure 3.6B). Thus, BRCA1 negatively regulates binding of BRD4 to DNA.
BRD4 functions broadly in the genome, but is specifically linked to oncogenes
like C-MYC, CCND1, KRAS, BCL2, and BRAF(65). To test whether BRD4 regulates
transcription of our plasmid substrate, pActin was incubated in extract supplemented
with buffer or an inhibitor of BET proteins called JQ1. JQ1 blocks interaction between
BRD4 and acetyl-histones, leading to global reorganization of BRD4 in cells(64). When
DNA-bound proteins were analyzed by plasmid pull-down, we saw that JQ1 severely
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Figure 3.6. BRCA1-BARD1 suppresses H4K8 acetylation and BRD4 binding. (A) pActin was incubated in
mock- or BRCA1-depleted extract. At the indicated time points, DNA-bound proteins were isolated by plasmid pulldown and analyzed by Western blot. Total recovery of plasmid DNA from mock- and BRCA1-depleted extracts is
shown in Figure S6. (B) pActin was incubated in extract supplemented with buffer or 200 nM BRCA1-BARD1 and
DNA-bound proteins were analyzed as in (A). (C) pActin was incubated in extract supplemented with buffer or JQ1
(BETi). At the indicated time points, DNA-bound proteins were analyzed as in (A). (D) pActin was incubated in
extract with increasing amounts of JQ1. After 120 minutes, RNA was quantified by RT-qPCR. (n=3) (E) pActin was
incubated in NPE supplemented with buffer or JQ1. At the indicated time points, RNA was quantified by RT-qPCR.
(F) pActin was incubated in extract supplemented with buffer or JQ1. Samples were withdrawn at the indicated time
points and analyzed by ChIP with BRG1 antibodies. (G-H) pActin was incubated in mock- or BRD4-depleted
extract. Samples were withdrawn for RNA isolation after 60 minutes in (G) or ChIP at the indicated time points in
(H). (I) pActin was incubated in mock- or BRD4-depleted extract supplemented with buffer or recombinant BRD4.
RNA was isolated after 60 minutes and analyzed by RT-qPCR. (J) pActin was incubated in mock- or BRCA1depleted extract. Samples were withdrawn after 20 minutes and analyzed by ChIP with the indicated antibodies
(n=2). (K) pActin was incubated in extract supplemented with buffer or JQ1. Samples were withdrawn after 20
minutes and analyzed by ChIP with the indicated antibodies (n=2).
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reduced BRD4 accumulation compared to a buffer control (Figure 3.6C). Transcription of
pActin was then quantified in reactions supplemented with buffer or JQ1. We found that
transcription was reduced by JQ1 in a dose-dependent manner (Figure 3.6D) and
remained inhibited for several hours (Figure 3.6E). JQ1 also reduced the recruitment of
the

ATPase

subunit

of

multiple

SWI/SNF

complexes,

BRG1

(Figure

3.6F),

complementing our mass spectrometry results (Figure 3.5B). Notably, we observe sitespecific recruitment of BRG1 to the promoter region of pActin (“PRO”) compared to a
site on the opposite side of the plasmid (“FAR”). Furthermore, immunodepletion of BRD4
resulted in a severely dramatic reduction in transcription from pActin (Figure 3.6 G-H).
This reduction can be rescued with the addition of recombinant human BRD4 (Figure 3.6
I). These results show that BRD4 is critical for transcription in our system. As such,
negative regulation of BRD4 by BRCA1 represents a major mechanism of transcription
suppression.
Association of BRD4 with chromatin is mediated primarily through its interaction
with acetylated histones. BRD4 was shown to have the highest affinity for acetylation of
histone H4 at lysines 5, 8, 12, and 16 (H4K5ac, H4K8ac, H4K12ac, and H4K16ac)(140).
To test whether BRCA1 regulates the formation of these chromatin marks, antibodies
that specifically recognize each modification were used to ChIP plasmid-bound proteins
in mock- or BRCA1-depleted reactions. We saw that BRCA1 depletion led to a
significant increase in the level of H4K8ac, but not H4K5ac, H4K12ac, or H4K16ac
compared to mock-depleted reactions (Figure 3.6J). BRD4 contains a histone acetyl
transferase (HAT) domain that has been linked to acetylation of multiple lysines on
histones H3 and H4(56). To test whether BRD4 also contributes to H4K8 acetylation in
extract, ChIP was performed in reactions supplemented with buffer or JQ1. Although
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binding of BRD4 was severely reduced in the presence of JQ1, the level of H4K5ac,
H4K8ac, H4K12ac, and H4K16ac did not decrease (Figure 3.6K), indicating that their
formation was not dependent on BRD4. Together, these results support a model where
BRCA1 regulates BRD4 binding by suppressing acetylation of histone H4K8.

3.3.f BRCA1-BARD1 may regulate BRD4 through p300
To confirm that BRCA1 functions through histone acetylation to regulate
transcription in extract, we supplemented mock- or BRCA1-depleted extract with the
pan-histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA). This
inhibitor dramatically increases acetylation of histone H3 and H4 tails in extract (data not
shown). Notably, in mock-depleted reactions we observed a ~2 fold increase in
transcription in the presence of SAHA (Figure 3.7A). However, the addition of SAHA did
not further increase the transcription of pActin in the absence of BRCA1. This result, as
well as the increase in H4K8Ac observed in Figure 3.6J, suggest BRCA1 is regulating
transcription by controlling histone acetylation..
BRD4 is often found at the same promoters as p300, a major histone
acetyltransferase (HAT) involved in cell growth and development(4, 138, 141). Indeed,
when we inhibit the DNA-localization of p300 by the small molecule inhibitor, SGCCBP30(142) (p300i), we see a decrease in DNA-bound BRD4 (Figure 3.7B). This result
suggests p300 is critical for normal recruitment of BRD4 to DNA.
Notably, p300 and BRCA1 functionally interact(123), and we observe this
interaction in extract (data not shown). The BRCA1-p300 interaction is mediated through
the BRCT domains of BRCA1. To test whether the BRCT domains of BRCA1 are
involved in transcription regulation, we supplement extract with peptides derived from
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the Abraxas protein that are designed to competitively bind the BRCT domains of
BRCA1 (P-Abraxas) or with unphosphorylated peptides that do not bind BRCTs
(Abraxas). Intriguingly, we see an increase in transcription in extracts supplemented with
P-Abraxas peptides compared to the unphosphorylated control peptides (Figure 3.7C).
This result suggests the BRCT domains of BRCA1 are important for transcription
suppression. Future studies will need to confirm whether these peptides disrupt the
interaction between BRCA1 and p300.
To formally implicate p300 in BRCA1-mediated transcription suppression, we
incubated pActin in mock- or BRCA1-depleted extract supplemented with buffer or
p300i. In mock-depleted reactions, treatment with p300i had minimal effect on
transcription (0.82x; Figure 3.7D). However, p300 inhibition significantly decreased
transcription in BRCA1-depleted reactions (0.46x; Figure 3.7D), indicating that p300
stimulates transcription in the absence of BRCA1. Future experiments will uncover the
relationship between p300 and BRCA1 in extract, and identify whether BRCA1-mediated
inhibition of p300 causes the observed defect in BRD4 recruitment.
Several regulatory mechanisms between BRCA1 and p300 involve the estrogenreceptor alpha (ERa)(143, 144). To test whether BRCA1-mediated transcription
suppression is dependent on ERa activity, we supplemented extract containing buffer or
excess BRCA1-BARD1 with buffer or the ERa inhibitor, endoxifin, and measured
transcription after 120 minutes (Figure 3.7E). As expected, the addition of recombinant
BRCA1-BARD1 decreased transcription. Interestingly, the addition of endoxifin greatly
decreased transcription in buffer-treated reactions (compare blue bars); suggesting ERa
plays a role in activating transcription in extract. However, the addition of endoxifin did
not dramatically affect the transcription in BRCA1-BARD1-supplemented reactions
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(compare yellow bars), suggesting BRCA1-BARD1 is inhibiting transcription in an ERadependent mechanism. Future work will uncover how ERa fits into the pathway we
present in this story and attempt to establish a molecular connection involving BRCA1,
p300, ERa, and BRD4.

3.4 Discussion
In Chapter 3, we report that BRCA1 suppresses transcription in Xenopus
nucleoplasmic extract. We show that BRCA1-mediated histone H2A ubiquitination is
dispensable, establishing the presence of an alternative mechanism. Although BRCA1BARD1’s ability to suppress transcription is not dependent on damage signaling, its
activity could be influenced by damage-dependent localization or expression of the
complex. Using mass spectrometry, we identified proteins whose DNA-binding was
regulated by BRCA1-BARD1 in extract (Figure 3.5A-B). We saw that BRD4, through
interactions with SWI/SNF, Mediator, P-TEFb, and the Super Elongation Complex, was
a potential candidate for regulation by BRCA1-BARD1 (Figure 3.5C). We then confirmed
that BRCA1-BARD1 was a negative regulator of BRD4 binding by Western blot (Figure
3.6A-B) and showed that inhibition of BRD4 binding was sufficient to block transcription
in our system (Figure 3.6C-E). BRD4 is recruited to active genes by acetyl-histones
where it acts as a scaffold, stabilizing the transcription pre-initiation complex and
stimulating elongation. When we looked at histone acetylations associated with BRD4
binding, we saw that BRCA1 specifically suppressed the level of H4K8ac (Figure 3.6J).
BRD4’s recruitment to chromatin likely involves interaction with multiple histone
acetylations(145). However, acetylation of H4K8 has been shown to greatly increase
BRD4’s overall affinity for other acetyl-marks(140). Thus, regulation of H4K8 acetylation
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by BRCA1 may act as a regulatory switch for the stable association of BRD4 with
chromatin. We also identify a potential role for the major HAT, p300, in the regulation
between BRCA1 and BRD4 (Figures 3.7B-D). This preliminary data sets up an
interesting model, in which BRCA1 suppresses p300 activity in extract. Future work will
determine the major epigenetic marks controlled by p300 in extract, and how these
marks are influenced by BRCA1 activity.
We show that BRD4 is essential for transcription in NPE (Figures 3.6G-I). As
such, NPE presents a unique setting to study BRD4 biology, allowing the analysis of
different functional domains, binding partners, and mutagenesis in a cell-free
transcription system.

BRD4 promotes expression of major oncogenes, establishing

inhibition of BRD4 and other BET proteins as an emergent therapeutic strategy(146).
Both BRCA1 loss, and BRD4 inhibition cause synthetic lethality with poly-ADP ribose
polymerase (PARP) inhibition(67, 147). Our findings connect BRCA1 with BRD4,
thereby identifying dysregulation of BRD4 as a common theme in both mechanisms of
genome-induced cell death. Establishing the mechanisms that underlie these genetic
interactions will continue to shed new light on the role they play in tumor suppression,
cancer development, and therapeutic intervention.
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Chapter 4: BRD4 promotes resection and homology-directed
repair of DNA breaks in Xenopus egg extract

4.1 Premise
DNA double-strand breaks (DSBs) are one of the most toxic forms of DNA
damage. These lesions can lead to aberrant chromosomal rearrangements and genetic
mutations, altering gene function and ultimately leading to cell death or tumor
transformation if not repaired properly. The cell has evolved two major pathways to
repair DSBs: non-homologous end joining (NHEJ) and homologous recombination
(HR)(148). Pathway choice is largely dictated by cell cycle stage, where HR is most
active in S and G2 phases due to the presence of sister chromatids(149). As HR uses
homologous DNA sequences for repair, it is largely considered “error-free”. In contrast,
NHEJ is often error-prone due to various end processing and ligation steps that do not
utilize a homologous template(150). Recent studies have suggested that these two
pathways are both active in S/G2 phases, suggesting that, although HR is normally
preferred, NHEJ mechanisms are active regardless of cell cycle progression(151).
Indeed, when NHEJ is inhibited HR is upregulated, suggesting that some amount of
G2/S DNA is repaired by NHEJ(152).
NHEJ-mediated repair is initiated by the binding of the Ku70/80 heterodimer to
broken DNA ends. Ku70/80 then recruits DNA-PKcs, a critical serine/threonine kinase
that helps tether broken DNA ends together. The DNA ends are ultimately restored after
end processing and ligation (reviewed in (150)). Conversely, DSBs that are repaired by
HR undergo 5’ end resection mediated by CtIP and the Mre11-Rad50-Nbs1 (MRN)
complex. The resulting 3’ ssDNA is coated with RPA, and a complex containing BRCA1-
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BRCA2-PALB2 promotes the exchange of RPA with the recombinase RAD51. These
RAD51-loaded nucleoprotein filaments facilitate homology-search and strand invasion,
using a homologous template to extend the damaged end. The resulting Holliday
junctions are ultimate settled by dissolution and resolution (reviewed in (153)).
The BET protein family consists of BRD2, BRD3, BRD4 and testis-specific
BRDT. These proteins are established epigenetic regulators that localize to DNA through
interaction with acetylated histone tails. Outside transcriptional regulation, these proteins
have been implicated in DNA replication and cell cycle control(154-156). The most
characterized BET protein, BRD4, has been shown to regulate various genes involved in
cellular growth and proliferation, including several oncogenes, such as MYC and
CCND1(65). BET inhibition is therefore an attractive target for anti-cancer therapeutics,
and several highly selective BET inhibitors have recently been developed(157).
Several recent studies have implicated BET proteins as important regulators
of DNA damage repair, DNA replication and telomere maintenance(65). Indeed, studies
have shown that expression of multiple HR genes is regulated by BRD4, including
BRCA1, RAD51, and CtIP(66, 67), and BET inhibition has been shown to sensitize cells
to PARP inhibitors(67, 158). Studies have also shown a role for BRD4 in the prevention
of R-loops and acting as a scaffold protein for NHEJ-mediated repair(159, 160).
Conversely, BRD4 has also been proposed to antagonize the DNA damage response by
creating compacted chromatin(161). Understanding the functional role that BET proteins
play in DNA repair remains an area of ongoing research.
In this chapter, we use Xenopus egg extracts to analyze DNA repair
mechanisms in the absence of global gene expression and cell cycle changes. We see
competition between the two major DNA repair pathways, HR and NHEJ, on post-
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replicative plasmid DNA. We show that BET inhibition disrupts HR-mediated repair
independent of RNA polymerase II (RNAPII) activity. Mechanistically, we show that BET
inhibition prevents the recruitment of the resection proteins, Mre11 and CtIP, to DNA and
dramatically reduces the amount of resected DNA. Furthermore, we show that BET
inhibition reduces nucleosome density at the site of damage, correlating with the
recruitment of the major SWI/SNF ATPase subunit, BRG1. By immunodepletion, we
show BRD4 is necessary for the DNA retention of both CtIP and BRG1, and we identify
a novel BRD4-CtIP-BRG1 complex in extract. These results identify a transcriptionindependent consequence of BET inhibition and a novel function of BRD4 in homologydirected DNA repair.

4.2 Methods and Materials
Antibodies, Immunodepletion, and Immunoprecipitation
Phosphorylated Chk1 antibodies were purchased from Cell Signaling (#2341). Histone
H3 antibodies were purchased from Thermo Fisher (PA5-16183). BRD2, BRD3 and
BRD4 antibodies were produced by New England Peptide. Mre11 and CtIP antibodies
were gifted from Jean Gautier and Richard Baer, respectively. BRG1 antibodies were
purchased from Bethyl Laboratories (A300-813A). RAD51 and RPA antibodies were
described previously(162). For depletion experiments, 10 µL of NPE was incubated with
4 µL of Protein-A Sepharose Fast Flow beads (GE Healthcare) that were pre-bound with
either 16 µL of pre-immune (mock) or αBRD4/αCtIP serum for 1 hour at 4°C. NPE
underwent two rounds of immunodepletion, before use. HSS was subject to one round of
depletion, and BRD4/CtIP-depleted HSS was used for both mock- and BRD4/CtIPdepleted NPE. For immunoprecipitation experiments, 5 µL of Protein-A Sepharose Fast
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Flow beads were pre-bound with either 5 µL of pre-immune (mock) or 5 µL αBRD4/αCtIP
serum. For BRG1 immunoprecipiations, 5 µL of Protein-A Sepharose Fast Flow beads
were pre-bound with either 1 µg purified rabbit IgG or 1 µg purified αBRG1 antibodies.
Beads were then incubated with 5 µL HSS/NPE mix that was diluted 7-fold in Egg Lysis
Buffer (ELB: 10 mM HEPES-KOH pH 7.7, 2.5 mM MgCl2, 50 mM KCl, and 250 mM
sucrose) containing 0.02% Tween-20 and rotated for 90 minutes at 4°C.

Replication Reactions
pCMV-GFP (Addgene ##11153) was used for all reactions. An EcoRV site was cloned in
this plasmid (QuikChange, Agilent) using the following primer pairs:
CGCTACCGGACTCAGATATCGAGCTCAAGCTT and
AAGCTTGAGCTCGATATCTGAGTCCGGTAGCG
HSS was supplemented with ATP Regeneration Mix (ARM; 6.5 mM phosphocreatine,
0.65 mM ATP, and 1.6 µg/mL creatine phosphokinase) and 10 µM nocodazole, while
NPE was supplemented with ARM and 3.5 mM DTT. Plasmids were incubated in HSS
for 20 minutes at room temperature (RT) then supplemented with NPE to induce
replication. The final plasmid concentration in each reaction was 2.5-5 ng/µL. Once NPE
is added, reactions are stored at room temperature (RT). Where indicated, reactions
were supplemented with 300 µM JQ1 (Sigma), 87 µM NU7441 (Selleckchem), 18 µM
BRC peptides, 0.25 U/µL AgeI (New England Biolabs), 0.91 U/µL KpnI (New England
Biolabs), 20 U/µL EcoRV (New England Biolabs), or 0.3 µCi/µL α32P[dATP]. For
radioactive reaction time points, 1 µL of reaction was diluted 6-fold in replication stop dye
(3.6% SDS, 18mM EDTA, 90 mM Tris pH 8, 90 mg/mL Ficoll, 3.6 mg/mL Bromophenol
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Blue) and treated with 20 mg proteinase K overnight at RT before agarose gel
electrophoresis.

2D Gel Electrophoresis
Reaction samples were diluted 10-fold in extraction stop solution (50 mM Tris pH 7.5, 25
mM EDTA, 0.5% SDS), treated with 4 mg RNase for 30 minutes at 37°C, then incubated
with 30 mg proteinase K overnight at RT. DNA was isolated by phenol/chloroform
extraction, followed by ethanol precipitation. Where indicated, the resulting DNA was
digested with AvrII (New England Biolabs). Samples were run on a 0.4% agarose gel at
1 V/cm for 14 hours. The gel was then stained with 0.3 µg/mL ethidium bromide, and
individual lanes were sliced out for 2D analysis. The 2nd dimension gel contained 1%
agarose and 0.3 µg/mL ethidium bromide and was cast around the 1st dimension slices.
The 2nd dimension gel was run in buffer containing 0.3 µg/mL ethidium bromide at 4
V/cm for 15 hours at 4°C. The gel was then dried and visualized by autoradiography.

Sequencing Analysis
DNA was purified from reactions 30 minutes after enzyme addition. Intact plasmids were
amplified by qPCR using primers that span the restriction enzyme sequence. qPCR
reactions were stopped in the linear range of amplification. The resulting 270 nucleotide
PCR fragments were isolated by gel electrophoresis and subsequent gel extraction
(Qiagen). Samples were sent to Genewiz for amplicon sequencing with variant detection
analysis.

The

primers

used

for

qPCR

amplification

were:

GGTAGGCGTGTACGGTGGGA and CGTAGGTGGCATCGCCCTCG
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RNA purification
RNA was isolated from extract using the EZNA RNA Purification kit (Omega Bio-tek).
cDNA was produced using QuantiTect Reverse Transcription kit (Qiagen) and then
analyzed by qPCR. RNA recovery was normalized to endogenous 18S rRNA. The
following primer pairs were used:

pActin (Promoter region):

CCCGCATAGAAAGGAGACA and
GCCAGAACATAGACATTAAGAAGG

18S rRNA:

GACCGGCGCAAGACGAACCA and
TGCTCGGCGGGTCATGGGAA

Plasmid Pull-Down
Plasmids were isolated from extract as described previously(80). Briefly, reaction
samples were added to LacI-coupled magnetic beads (Dynabeads M-280; Invitrogen)
suspended in LacI pull-down buffer (10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM MgCl2,
250 mM sucrose, 0.25 mg/mL BSA, and 0.02% Tween 20). Samples were rotated at 4°C
for 20 minutes, washed three times with LacI wash buffer (10 mM HEPES pH 7.7, 50
mM KCl, 2.5 mM MgCl2, 0.25 mg/mL BSA, and 0.02% Tween 20), dried, and
resuspended in 2x SDS buffer (100 mM Tris-HCl pH 7.5, 20% glycerol, 4% SDS, 200
mM β-mercaptoethanol, and 0.2% bromophenol blue). DNA-bound proteins were then
resolved by SDS-PAGE, and visualized by Western blotting with the indicated
antibodies.
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Chromatin Immunoprecipitation
ChIP was performed as described previously(130). Briefly, reaction samples were
crosslinked in ELB containing 1% formaldehyde. Crosslinking was stopped with the
addition of 125 mM glycine and excess formaldehyde was removed with a Micro BioSpin 6 chromatography column (Bio-Rad). Samples were sonicated (Diagenode
Bioruptor UCD-600 TS) and immunoprecipitated with the indicated antibodies.
Crosslinks were then reversed, and the resulting DNA was isolated by phenol/chloroform
extraction and ethanol precipitation. Total (INPUT) and recovered DNA were analyzed
by qPCR. The following primers were used, which are located 50 nts downstream of the
AgeI sequence:
CGCTACCGGACTCAGATATCGAGCTCAAGCTT and CGTAGGTGGCATCGCCCTCG

4.3 Results
4.3.a HR and NHEJ compete for repair of DNA ends in Xenopus egg extract
To investigate the role of chromatin signaling in double-strand break (DSB)
repair, we sought to establish a system for inducing a single, site-specific DSB in
Xenopus egg extracts. A variety of restriction enzymes were tested for their ability to
cleave plasmid DNA incubated in extract (data not shown). We identified AgeI, KpnI, and
EcoRV, which readily cleaved DNA to produce ends with 5’, 3’, or blunt overhangs,
respectively. The recognition sequence for each enzyme was then cloned onto a single
plasmid, termed pDSB (Figure 4.1A).
To monitor the formation and repair of DSBs, pDSB was replicated in the
presence of radiolabeled nucleotide ([α-32P] dATP) by first incubating in HSS (High
Speed Supernatant) to promote formation of pre-Replication Complexes (pre-RCs), and
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Figure 4.1. DNA ends are readily repaired in extract. (A) Schematic of pDSB with primer sites and restriction
digest sites labeled. Sequences and end orientation of AgeI, KpnI and EcoRV are shown. (B) pDSB was
replicated in the presence of α32P[dATP] and supplemented with AgeI. Samples were drawn at the indicated time
points and visualized by gel electrophoresis and autoradiography. Replication intermediates, supercoiled (SC),
linear, open circular (OC), and high molecular weight (HMW) plasmid topologies are indicated. (C-D)
Quantification of linear (C) and HMW (D) bands from (B). (E) pDSB was replication and supplemented with AgeI.
Samples were isolated at the indicated time points and analyzed by Western blot with the indicated antibodies.
(F) pDSB was replicated in the presence of α32P[dATP] and supplemented with KpnI. Samples were drawn at the
indicated time points and visualized by gel electrophoresis and autoradiography. (G-H) Quantification of linear (G)
and HMW (H) bands from (F). (I) pDSB was replication and supplemented with KpnI. Samples were isolated at
the indicated time points and analyzed by Western blot with the indicated antibodies. (J) pDSB was replicated in
the presence of α32P[dATP] and supplemented with EcoRV. Samples were drawn at the indicated time points and
visualized by gel electrophoresis and autoradiography. (K-L) Quantification of linear (K) and HMW (L) bands from
(J). (M) pDSB was replication and supplemented with EcoRV. Samples were isolated at the indicated time points
and analyzed by Western blot with the indicated antibodies.
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then adding NPE (Nucleoplasmic Extract) to induce origin firing(9). DNA was isolated at
various times throughout the reaction, resolved by agarose gel electrophoresis, and
visualized by autoradiography (Figure 4.1B). Replication was completed within ~20
minutes, leading to the formation of open circular (OC) and supercoiled (SC) plasmids.
After 45 minutes, the reaction was split and supplemented with buffer or AgeI to induce
DSB formation. In the presence of AgeI, over 50% of plasmids were linearized within 5
minutes, indicating the presence of a DSB (Figure 4.1B, lane 11; Figure 1C). After 60
minutes, there was a decrease in the accumulation of linear molecules and a
corresponding increase in high molecular weight structures consistent with homologous
recombination(162) (Figure 4.1B and D). AgeI addition and DSB formation also
coincided with Chk1 phosphorylation (Figure 4.1E), indicating DSB-dependent induction
of damage signaling(163). Similar results were also observed in reactions supplemented
with KpnI (Figure 4.1F-I) or EcoRV (Figure 4.1J-M), showing different DSB overhangs
readily activate damage signaling and repair in extract.
To further examine the intermediates formed after DSB induction, DNA was
isolated 90 minutes after the addition of buffer or AgeI. Samples were then digested with
AvrII, resolved by 2D agarose gel electrophoresis, and visualized by autoradiography
(Figures 4.2A-B). In the buffer control, AvrII digestion resolves the majority of
intermediates into a 1x linear spot. In AgeI-treated reactions, we saw the expected DSB
fragments produced by AgeI cleavage (Figure 4.2A; “Short” and “Long”), which form a
“comet” shape due to resection of DNA ends(164). We also saw an accumulation of
branched intermediates consistent with homologous recombination, and two spots
consistent with mismatched joining of “Short-Short” or “Long-Long” DSB fragments by
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Figure 4.2. HR and NHEJ compete for repair of DNA ends in Xenopus egg extract. (A) Schematic of AvrIIdigested 2DGE figures.(B) pDSB was replicated in the presence of α32P[dATP]. Reactions were supplemented with
buffer control, BRC peptides (RAD51i), or NU7441(DNA-PKi). After 45 minutes, reactions were supplemented with
AgeI or storage buffer. Samples were withdrawn 90 minutes after AgeI addition, digested with AvrII and analyzed
by 2DGE and autoradiography. (C) pDSB was replicated in the presence of α32P[dATP]. Reactions were
supplemented with buffer control or BRC peptides (RAD51i). Samples were withdrawn at the indicated time point
and visualized by gel electrophoresis and autoradiography. (D-E) Quantification of linear (D) and HMW (E)
products from (C). (F) pDSB was replicated in the presence of α32P[dATP]. Reactions were supplemented with
buffer control or NU7441 (DNA-PKi). Samples were withdrawn at the indicated time point and visualized by gel
electrophoresis and autoradiography. (G-H) Quantification of linear (G) and HMW (H) products from (F). (I-L) pDSB
was replicated in extract supplemented with either buffer control or NU7441 (DNA-PKi) for 45 minutes. Then
reactions were supplemented with either AgeI, KpnI or EcoRV. Samples were withdrawn after 30 minutes and
analyzed by amplicon sequencing (see Methods). Insertations products are graphed in (I), and deletion products
for AgeI, KpnI and EcoRV reactions are graphed in (J-L), respectively.
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NHEJ. The appearance of both HR and NHEJ products argues that both repair
pathways are active in extract and likely compete for DNA ends.
To test whether formation of branched intermediates was HR-dependent, AgeI
reactions were supplemented with BRC peptides derived from BRCA2, which disrupt
RAD51 filament formation and block homologous recombination(162, 165-168). In the
presence of BRC peptides, the accumulation of branched intermediates was severely
reduced compared to the buffer control (Figure 4.2B). When DNA was resolved by 1D
gel (as in Figure 4.1B), formation of the corresponding high molecular weight
intermediates was also blocked by the addition of BRC peptides (Figures 4.2C and E).
Consistent with decreased recombination, we see a slight increase in linearized DNA in
BRC-supplemented reactions (Figure 4.2D). These results confirm that the AgeI-induced
branched intermediates were bona fide HR products.
We also supplemented AgeI reactions with the DNA-PKcs inhibitor NU7441
(DNA-PKi)(169). DNA-PKcs is recruited to DSBs by the Ku70-Ku80 heterodimer to form
DNA-PK, a synaptic complex that tethers broken DNA ends and primes them for
ligation(170). In the presence of DNA-PKi, the accumulation of branched intermediates
increased compared to the buffer control (Figure 4.2B). In 1D gels, addition of DNA-PKi
showed a slight increase in high molecular weight intermediates (Figures 4.2F and H)
and a reduction in OC and SC bands (Figure 4.2F). We also see a slight decrease in
linearized plasmids at later time points (Figure 4.2G), consistent with increased invasion
and recombination. These results indicate that DNA-PKcs normally antagonizes HR
activity in extract and that, when inhibited, an increased number of plasmids undergo
strand invasion to form branched intermediates.

78

To further investigate the interplay between HR and NHEJ in extract, we used
amplicon sequencing to analyze the DSB junction (Figure 4.1A) of intact plasmids
following the addition of AgeI, KpnI, or EcoRV. DNA was isolated 30 minutes after
restriction enzyme addition to avoid excessive amplification of existing products by HR
that occurs after 60 minutes. For AgeI digestion, we saw an accumulation of DNA
insertions at the AgeI site under buffer conditions that were abrogated with DNA-PKi
(Figure 4.2I). The majority of these insertions contained a duplication of the AgeI
recognition sequence, suggesting that gap-filling, followed by end ligation is a classical
NHEJ mechanism occurring in extract. Additionally, we saw deletion products spanning
the AgeI sequence. Based on sequence analysis, these products likely represent microhomology mediated end joining (alternative end joining; (a-EJ)). The majority of deletion
products resulted in the loss of 10+ nucleotides spanning the AgeI sequence (Figure
4.2J). Notably, a-EJ products increased with the addition of DNA-PKi, consistent with
previous literature(152). Conversely, when plasmid products were sequenced after KpnI
digest (which creates 3’ overhangs), we saw little insertion or deletion products
regardless of DNA-PKi treatment (Figures 4.2I and K). This result suggests that 3’ ends
undergo less end processing compared to 5’ ends, presumably as 3’ ends are already
primed for HR-mediated strand invasion. We observed even less insertion or deletion
products after EcoRV digestion (Figures 4.2I and L), which creates blunted DNA ends.
This result is to be expected, as there is no ssDNA overhang to process with EcoRV
digestion. Collectively, these data indicate that the HR, canonical-NHEJ, and alternativeEJ pathways all active in extract, and the choice between repair pathways can be
influenced by end orientation.
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4.3.b BET inhibition specifically disrupts HR-mediated repair
Recent reports have identified BET proteins as important regulators of DNA
repair through their ability to upregulate expression of multiple repair factors in response
to damage(65-67, 160). To investigate whether BET proteins play a transcriptionindependent role in DNA repair, we supplemented reactions with buffer or the BET
inhibitor, JQ1. JQ1 (BETi) is an acetyl-lysine mimic that blocks interaction of BET
proteins with chromatin(64, 171). In the presence of BETi, DNA synthesis occurred
normally (Figure 4.3A, compare lanes 1 and 2). However, BET inhibition severely
reduced the accumulation of high molecular weight HR products formed after AgeI
treatment (Figures 4.3A and C). Consistent with a defect in recombination, we see an
increase in linearized plasmids at later time points in BETi-treated reactions (Figures
4.3A and B). BET inhibition also led to an accumulation of smaller intermediates that
resemble invasion or ligation products between two plasmid substrates(172) (Figure
4.3A, “LMW”). Additionally, treatment with BETi reduced phosphorylation of Chk1,
suggesting a dysfunction in DNA damage signaling events (Figure 4.3D). Similar results
were also obtained in reactions where DSBs were generated by KpnI and EcoRV (data
not shown). These results argue that BET proteins play a critical role in supporting
homology-directed repair of DSBs containing 5’, 3’, and blunt overhangs.
To test whether BET inhibition also influenced repair of DSBs by NHEJ, we
isolated the DNA products from AgeI reactions supplemented with buffer or BETi for
amplicon sequencing. We observed similar levels of DNA-PKcs-dependent insertion
products in buffer and BETi-treated reactions (Figure 4.3E), indicating that BET inhibition
did not alter the end joining of extended overhangs. Additionally, we observed a
decrease in 10+ nucleotide deletion (a-EJ) products in the presence of JQ1 (Figure
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Figure 4.3. BET inhibition specifically disrupts HR-mediated repair. (A) pDSB was replicated in extract
supplemented with α32P[dATP]. Reactions were treated with buffer control or JQ1 (BETi) and supplemented with
AgeI after 45 minutes. Samples were withdrawn at the indicated time points and visualized by gel electrophoresis
and autoradiography. (B-C) Quantification of linear (B) and HMW (C) products from (A). (D) pDSB was replicated
in extract treated with buffer control or JQ1 (BETi) and supplemented with AgeI after 45 minutes. Samples were
withdrawn at the indicated time points and analyzed by Western blot with the indicated antibodies.(E-F) pDSB
was replicated in extract supplemented with either buffer control or JQ1 (BETi) for 45 minutes. Then reactions
were supplemented with AgeI, and samples were withdrawn after 30 minutes and analyzed by amplicon
sequencing (see Methods). Insertion products are presented in (E) and deletion products are presented in (F).
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4.3F), suggesting resection of DNA ends may be disrupted in BETi reactions. Altogether,
these results indicate the role BET proteins play in DSB repair is likely tied to HR.

4.3.c Transcription is dispensable for BET-mediated repair of DSBs
We recently showed that Xenopus nucleoplasmic extract (NPE) can support
transcription of plasmid substrates(128). We found that replication reactions (which have
been used throughout this chapter) transcribe considerably less compared to NPE-alone
reactions; however, the RNAPII inhibitor α-amanitin was still able to reduce the level of
transcription in replication reactions (Figure 4.4A). The significant decrease in
transcription between the reaction set-ups is likely due to the intrinsic anti-transcription
activity of HSS (refer to Figures 2.1B and E). However, the process of replication may
“wipe-out” any active transcription complexes, and chromatin modifications that occur as
a result of replication may inhibit transcription initiation. This is likely to be explored in
future studies.
To formally test whether active transcription plays a role in BET-mediated
repair in our replication system, AgeI reactions were supplemented with buffer, αamanitin, BETi, or both α-amanitin and BETi. We found that blocking RNAPII-mediated
transcription had no effect on the normal accumulation of high molecular weight HR
intermediates (Figure 4.4B, compare lanes 1-6 with 7-12), and did not influence the
effects of BETi described above (Figure 4.4B, compare lanes 1-12 with 13-24; Figures
4.4C and D). These results indicate that RNAPII is dispensable for DSB repair in extract,
demonstrating that BET proteins support a transcription-independent role in HR.
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Figure 4.4. Transcription is dispensable for BET-mediated repair of DSBs. (A) pActin was incubated in NPE
or replicated in NPE/HSS in the presence of buffer control or α-amanitin. RNA was isolated after 120 minutes and
analyzed by RT-qPCR. (B) pDSB was replicated in the presence of α32P[dATP]. Reactions were supplemented
with α-amanitin, JQ1 (BETi), or a combination of α-amanitin and JQ1, and AgeI was added after 45 minutes.
Samples were withdrawn at the indicated time points after AgeI addition and analyzed by gel electrophoresis and
autoradiography. (C-D) Quantification of linear (C) and HMW (D) products from (B).
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4.3.d BET inhibition prevents CtIP-MRN localization and DNA end resection
To investigate how BET inhibition disrupts HR, we analyzed DNA-bound
proteins by plasmid pull-down from AgeI reactions supplemented with buffer or BETi and
visualized them by Western blot. BRD4 is actively bound to our plasmid substrate prior
to AgeI cleavage (Figure 4.5A, lane 3), and as expected, DNA binding of the BRD4 was
blocked in the presence of BETi(171) (Figure 4.5A, compare lanes 3-7 with 8-12). We
also saw that BET inhibition severely reduced DNA binding of the resection nucleases
CtIP and Mre11. DNA binding of the single-strand binding protein RPA as well as the
recombinase RAD51 was also reduced, consistent with a failure to resect DNA ends.
The total level of each protein blotted was unchanged throughout the reaction (Figure
4.5B, compare lanes 1-5 with 6-10), indicating that BET inhibition disrupted protein
localization but not protein degradation.
To examine the extent of resection at AgeI-induced breaks in reactions
supplemented with buffer or BETi, undigested DNA intermediates were resolved by 2D
agarose gel electrophoresis. Resection of the linear band (produced by AgeI cleavage)
creates a downward “tail” due to the reduced size of the fragment (Figure 4.5C). In the
presence of BETi, the intensity of the resected tail was reduced (Figures 4.5D and E),
indicating that BET inhibition reduced the extent of DNA end resection in extract.
CtIP has been studied extensively for its role in stimulating DNA end resection
that commits the DSB to HR-mediated repair(173, 174). To formally test that CtIP plays
a similar role during repair of AgeI-induced breaks in our system, we immunodepleted
CtIP from HSS and NPE prior to the reaction (Figure 4.6A). In the absence of CtIP,
accumulation of high molecular weight HR intermediates was severely reduced (Figure
4.6B, compare lanes 4-7 with 12-15; Figure 4.6D), similar to that observed in JQ1-
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Figure 4.5. BET Inhibition prevents CtIP-MRN localization and DNA end resection. (A) pDSB was replicated
in extract supplemented with buffer control or JQ1 (BETi). AgeI was added after 45 minutes, and DNA-bound
proteins were isolated at the indicated time points. Samples were analyzed by Western blot with the indicated
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Schematic for undigested 2DGE. (D) pDSB was replicated in the presence of α32P[dATP] in extract supplemented
with buffer control or JQ1 (BETi). AgeI was added after 45 minutes. Samples were withdrawn 30 minutes after
AgeI-addition and analyzed by 2DGE and autoradiography. (E) Quantification of the linear plasmids in (D).
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2

3

4

treated reactions (Figure 4.3A). CtIP depletion also prevented the accumulation of tail
intermediates in 2D gels (Figures 4.6E and F), indicating that resection of the AgeIinduced break was completely blocked. Together, these data show that BET inhibition
disrupts the recruitment of the resection machinery, which is essential for DNA end
resection and HR-mediated repair.

4.3.e BET inhibition disrupts BRG1 recruitment and displacement of histones from
DSBs
Chromatin remodeling is an essential component of the DNA damage
response that allows repair machinery to access the site of DNA damage(175). To
investigate whether BET proteins regulate resection by altering chromatin structure, AgeI
reactions were supplemented with buffer or BETi and histone binding was analyzed by
ChIP (Figure 4.1A). Binding of histone H3 to the DSB site was reduced rapidly following
addition of AgeI (Figure 4.7A, blue trace). In contrast, BET inhibition delayed removal of
histone H3 from the break site for up to 10 minutes before histone levels began to drop
(Figure 4.7A, orange trace). This result indicates that BET proteins play an important
role in chromatin remodeling at DSB sites upstream of DNA end resection.
SWI/SNF chromatin remodeling complexes are heavily implicated in the
removal of nucleosomes during DSB repair(176-179). SWI/SNF complexes contain one
of two ATPase subunits, BRM or BRG1, which are essential for its chromatin remodeling
activity(180). BRG1, specifically, has been linked to BET proteins through direct
interaction and common molecular pathways(141, 181-183). To test whether BET
inhibition affects recruitment of BRG1 to chromatin, protein binding was analyzed by
ChIP before and after DSB formation. In control reactions, BRG1 binding increased
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Figure 4.7. BET inhibition disrupts BRG1 recruitment and displacement of histones from DSBs. (A) pDSB
was replicated in extract supplemented with buffer control or JQ1 (BETi). After 45 minutes, AgeI was added.
Samples were withdrawn for ChIP at the indicated time points. (B) pDSB was replicated in extract supplemented
with buffer control or JQ1 (BETi). After 45 minutes, AgeI was added. Samples were withdrawn for ChIP at 0 and 2
minutes after AgeI addition. (C) pDSB was replicated in the presence of α32P[dATP] in extract supplemented with
buffer control or BRG1/BRM ATP Inhibitor-1 (SWI/SNFi). After 45 minutes, reactions were supplemented with
AgeI. Samples were withdrawn at the indicated time points and analyzed by gel electrophoresis and
autoradiography. (D-E) Quantification of linear (D) and HMW (E) products from (C). (F) pDSB was replicated in
extract supplemented with buffer control or BRG1/BRM ATP Inhibitor-1 (SWI/SNFi). After 45 minutes, reactions
were supplemented with AgeI. Samples were withdrawn for ChIP at the indicated time points. (G) pDSB was
replicated in extract supplemented with buffer control or BRG1/BRM ATP Inhibitor-1 (SWI/SNFi). After 45
minutes, reactions were supplemented with AgeI. DNA-bound proteins were isolated by plasmid pulldown at the
indicated time points and analyzed by Western blot with the indicated antibodies. (H) pDSB was replicated in the
presence of α32P[dATP] in extract supplemented with buffer control or BRG1/BRM ATP Inhibitor-1 (SWI/SNFi).
After 45 minutes, reactions were supplemented with AgeI. Samples were withdrawn at the indicated time points
and analyzed by 2DGE and autoradiography. (I) Quantification of the linear tails in (H).
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~2.5-fold after AgeI addition (Figure 4.7B). However, AgeI-dependent BRG1 recruitment
was completely blocked in BETi-supplemented reactions.
To test whether the downstream repair defects associated with BET inhibition
are due to loss of SWI/SNF activity, we supplemented extract with buffer or the
BRG1/BRM ATP Inhibitor-1 (SWI/SNFi), which inhibits both SWI/SNF ATPase
subunits(184). DNA intermediates were isolated at various times after AgeI addition and
resolved by agarose gel electrophoresis. Compared to the buffer control, BRG1/BRM
inhibition led to a severe reduction in high molecular weight HR products and an
increased accumulation of the smaller branched intermediates (Figure 4.7C, compare
lanes 4-6 and 11-13; Figure 4.7E). These defects resemble those associated with BET
inhibition (Figure 4.3A), arguing that failure to recruit SWI/SNF complexes is, in part,
responsible for the repair defects caused by inhibition of BET proteins.
To further investigate the mechanism of SWI/SNF-mediated repair, binding of
histone H3 was analyzed by ChIP. Compared to a buffer control, reactions
supplemented with BRG1/BRMi showed a slight delay in histone H3 displacement after
AgeI addition (Figure 4.7F). DNA-bound proteins from buffer- or SWI/SNFi-treated
reactions were also analyzed by plasmid pull-down. Following AgeI addition, BRG1/BRM
inhibition significantly reduced the accumulation of RAD51(185) and slightly reduced the
recruitment of CtIP (Figure 4.7G, compare lanes 3-5 and 6-8). Unlike JQ1-treated
reactions, RPA accumulation still occurred in the presence of SWI/SNFi, but was slightly
delayed compared to the buffer control (compare RPA blots in Figures 4.7G and 4.5A).
Consistent with this result, we observed a subtle delay in the accumulation of ssDNA by
2DGE in reactions supplemented with SWI/SNFi (Figures 4.7H and I). By 60 minutes,
there was a striking decrease in the level of DNA-bound histone H3, BRG1, and BRD4 in
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SWI/SNFi-treated reactions, as well as an accumulation of DNA-bound RPA (Figure
4.5G, compare lanes 5 and 8). Similarly we observed a dramatic increase in ssDNA in
SWI/SNFi-treated reactions by 45 minutes (Figure 4.7I). Collectively, these results argue
that inactivation of SWI/SNF ATPase activity delays, but not blocks, resection of DNA
ends by CtIP that generates RPA-coated ssDNA. Failure to load RAD51 and promote
HR then leads to more extensive resection that includes displacement of histones and
chromatin-associated proteins like BRD4.

4.3.f BRD4 promotes resection and homology-directed repair of DSBs
The majority of studies involving BET proteins rely on inhibitors that do not
discriminate between individual proteins. To investigate the specific contributions of BET
proteins BRD2, BRD3, and BRD4 in DSB repair, we raised antibodies against each
protein. Although BRD2 and BRD3 antibodies did not support immunoprecipitation (data
not shown), BRD4 antibodies were able to efficiently deplete nearly all BRD4 from
extract without co-depletion of BRD2 or BRD3 (Figure 4.8A). We then isolated DNA
intermediates from AgeI reactions incubated with mock- or BRD4-depleted extracts and
resolved them by agarose gel electrophoresis. In the absence of BRD4, DNA replication
occurred normally (Figure 4.8B, compare lanes 1 and 9). However, loss of BRD4
reduced the accumulation of high molecular weight HR intermediates and delayed
resolution of linearized fragments, compared to the buffer control (Figure 4.8B,
quantified in 4.8C and D). These defects are consistent with those observed in JQ1treated reactions (Figure 4.3A), although not as severe. To further investigate the effects
of BRD4 loss, we then analyzed DNA-bound proteins in mock- or BRD4-depleted
reactions by plasmid pull-down. In the absence of BRD4, DNA binding of CtIP was
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Figure 4.8. BRD4 promotes resection and homology-directed repair of DSBs. (A) Different amounts of
mock-depleted (ΔMock) or BRD4-depleted (ΔBRD4) NPE was analyzed by Western blot using the indicated
antibodies. (B) pDSB was replicated in the presence of α32P[dATP] in mock- or BRD4-depleted extract. After 60
minutes, reactions were supplemented with AgeI. Samples were isolated at the indicated time points and
analyzed by gel electrophoresis and autoradiography. (C-D) Quantification of linear (C) and HMW (D) products
from (B). (E) pDSB was replicated in mock- or BRD4-depleted extract. After 60 minutes, reactions were
supplemented with AgeI. DNA-bound proteins were isolated by plasmid pulldown at the indicated time points and
analyzed by Western blot with the indicated antibodies. (F-H) Quantification of DNA-bound BRG1, CtIP and RPA
from (E), respectively.
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reduced and recruitment of RPA was delayed (Figure 4.8E, quantified in Figures 4.8G
and H). Additionally, BRD4-depletion reduced the amount of DNA-bound BRG1 after
AgeI cleavage (Figure 4.8F). The milder effects of BRD4 depletion could be due to
residual endogenous protein and/or partial compensation by BRD2 or BRD3, which are
also inhibited by JQ1. However, these results specifically implicate BRD4 in promoting
the resection and homology-directed repair of DSBs.

4.3.g Interactions between BRD4-BRG1-CtIP
To further explore the relationship between BRD4 and downstream effectors
of DSB processing and repair, we immunoprecipitated BRD4, BRG1, or CtIP from
HSS/NPE and analyzed recovery of associated proteins by Western blot. We saw that
immunoprecipitation of BRD4 specifically co-immunoprecipitated both BRG1 and CtIP
compared to non-specific IgG controls (Figure 4.9A). Reciprocal immunoprecipitations
with CtIP (Figure 4.9B) and BRG1 (Figure 4.9C) also recovered BRD4, BRG1, and CtIP.
Each immunoprecipitation was also analyzed with RPA antibodies to identify a protein
we would expect to have little to no interaction with BRD4, CtIP or BRG1. Indeed, we
see similar levels of residual RPA in both mock and protein-specific immunoprecipitation
pellets. The recovery of associated proteins from each immunoprecipitation are modest,
suggesting that only a small fraction of total protein is found in complex in the absence of
DNA. Indeed, we showed in Figure 4.8A that BRD4 depletion did not co-deplete either
CtIP or BRG1 from extract. Together, these results support a model where interactions
between BRD4-BRG1-CtIP facilitate a regulated response to DSB formation, either by
recruiting an intact complex or facilitating interaction between these proteins on
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Figure 4.9. Interactions between BRD4-BRG1-CtIP. (A-C) Extract was immunoprecipitated with beads
conjugated to BRD4 (A), CtIP (B), BRG1 (C) or mock antibodies. Bead-bound proteins were analyzed by Western
blot with the indicated antibodies. (D) Crosstalk between BRD4-BRG1-CtIP in coordinating HR repair through
nucleosome eviction, DNA end resection, and recombination.
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chromatin to promote efficient resection of DNA ends and subsequent repair by
homologous recombination (Figure 4.9D).

4.4 Discussion
In Chapter 4, we establish an in vitro system to study DNA double strand repair
using Xenopus egg extract. We show broken ends are readily repaired in a synchronized
fashion, regardless of end orientation (Figure 4.1). Furthermore, we show several repair
mechanisms

compete

for

DNA

ends

in

our

system,

including

homologous

recombination, non-homologous end joining, and alternative end joining (Figure 4.2).
Our DSB system resembles S phase, as our plasmid substrates are replicated prior to
DSB-formation. Indeed, NPE itself is considered an S phase extract, as it is produced
following replication of sperm chromatin. As such, we would expect HR to be the
predominant repair pathway. We do see the majority of our plasmid substrates are
ultimately used for HR (Figure 4.1B, lanes 15-17); however the presence of NHEJ and aEJ in this system validate several reports suggesting HR-independent repair
mechanisms are present throughout the entire cell cycle(186, 187).
Studies of BET proteins are often tied to their roles as epigenetic regulators.
BRD4 has been shown to control the transcription of several DNA repair proteins,
including CtIP, BRCA1, and RAD51(66, 67); thus BET inhibition often creates an HRdeficient phenotype. We show, in a defined system with no gene expression changes,
that BET inhibition impairs HR (Figure 4.3), suggesting BET proteins have an active role
in DSB repair, independent from their established role in gene regulation (Figure 4.4).
Although BRD4 has been implicated in NHEJ repair(159, 188), we see little or no
change in NHEJ-mediated insertion products under BET inhibition (Figure 4.3E). This
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difference could be attributed to the systems used in these studies, as well as cell cycle
stage (S phase extract vs unsynchronized cells). We also see a decrease in
phosphorylated-Chk1 levels with JQ1 (Figure 4.3D). The effect of BET inhibition on
ATR/ATM signaling has been met with conflicting reports(189, 190); however we did not
further investigate this relationship in this study.
We characterize HR repair in the presence of BET inhibitors, ultimately
identifying defects in DNA end resection (Figure 4.5) and nucleosome eviction (Figure
4.7). With BETi-treated reactions, we see decreased recruitment of two major proteins
involved in these pathways, CtIP and BRG1, respectively. We formally show CtIP is
critical for DNA end resection and subsequent HR repair through immunodepletion
experiments (Figure 4.6). Then, we show small molecule inhibition of the ATPase
subunits of BRG1/BRM (SWI/SNFi) slightly delays nucleosome eviction and subsequent
resection (Figure 4.7). BRG1 has been heavily implicated in nucleosome eviction in
response to DSBs(176-178); while BRM is thought to play little or no role in this
process(177). Interestingly, we see only a subtle delay in nucleosome eviction when
BRG1 is inhibited, suggesting the presence of an alternative/compensation mechanism.
Notably, we see BRD4 is still retained on DNA when BRG1 is inhibited (Figure 4.7G),
and BRD4 itself has nucleosome eviction capability(56). Therefore, it is plausible that
BRD4 compensates for inactive BRG1.
Whether BRG1 functions upstream or downstream of DNA end resection has
been met with conflicting results in cells (176-178, 185). Notably, the major defect we
see under SWI/SNFi is defective RAD51 loading (Figure 4.7G), which mimics the
addition of BRC peptides (compare Figures 4.7C and 4.2C). Although slightly delayed,
nucleosome eviction and DNA end resection still occur even in the presence of
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SWI/SNFi, showing that the major function of BRG1/BRM ATPase activity occurs
downstream of DNA end resection in extract.
We then formally implicate BRD4 in DNA repair, showing a reduction in HRmediated repair products and decreased recruitment of both CtIP and BRG1 when
BRD4 is depleted (Figure 4.8). These defects occur even in the presence of the
remaining BET proteins, BRD2 and BRD3, although we cannot rule out the possibility
that these proteins contribute to repair in some way. Notably we observe similar extents
of linearized plasmids soon after AgeI addition in the absence of BRD4 (Figure 4.8C),
suggesting that BRD4 does not affect the accessibility of our plasmid DNA to restriction
digest. We see that BRD4 is enriched on the DNA after replication; however its DNAretention is decreased after a DSB is formed (Figures 4.5A and 4.8E). This could be due
to the removal of histones around the damage site, which act as the binding scaffold for
BRD4 (Figure 4.7A). Conversely, this may be explained by a change in localization of
BRD4-complexes in response to DNA damage.
Finally, we functionally connect the major proteins, CtIP, BRG1, and BRD4, by
showing the first interaction between all three by co-immunoprecipitation experiments
(Figure 4.9). This interaction is observed in extract regardless of DNA; however the
association between these proteins may be influenced by DNA damage. This interaction
underscores the crosstalk between major steps in DNA repair, and implicates BRD4 as a
coordinator of HR repair. Ultimately, this work highlights a novel function of BET proteins
in controlling the initiation of DNA end resection, and functionally characterizes the
mechanisms of nucleosome eviction, DNA end resection, and recombination in a defined
system.
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Chapter 5: BET inhibition disrupts translesion synthesis during
inter-strand crosslink repair by preventing the DNA localization
of CtIP

5.1 Premise
DNA inter-strand crosslinks (ICLs) are toxic lesions that covalently bind
two adjacent strands of DNA, creating a barrier to DNA replication
machinery(191). As such, cells must repair these lesions in order to faithfully
replicate their DNA, and defects in the repair of ICLs can lead to genomic
instability.
The majority of ICLs are repaired during DNA replication, although
mechanisms for replication-independent ICL repair are proposed(192, 193). For
replication-coupled ICL repair, DNA replication forks converge at the site of the
crosslink(194), and the ubiquitin-selective segregase, p97, helps promote the
disassembling of replication complexes to allow access of repair machinery to
the crosslinked lesion(80). Then, FANCI-FANCD2, along with other members of
the Fanconi anemia pathway, promote DNA incisions that unhook the ICL from
one strand of DNA(195) creating a ssDNA gap and DNA double strand break.
The resulting ssDNA gap is filled in by translesion polymerases, Rev1 and
Rev7(196), while the double strand break is repaired by homologous
recombination(162).
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Bromo and extraterminal domain (BET) proteins include BRD2, BRD3,
BRD4 and the testis-specific BRDT. Traditionally these proteins are classified as
epigenetic regulators that function broadly in the genome. Notably, BET inhibitors
have shown anti-cancer activity for a variety of cancer types(197). Studies have
shown BET proteins control the transcription of several oncogenes, and
restricting the chromatin-binding of BET proteins with small molecule inhibitors
has ultimately slowed the proliferation of cancer cells. Recently, increasing
evidence has implicated BET proteins in functional roles outside of transcription
regulation, including DNA repair and telomere maintenance(65). How these
transcription-independent functions contribute to cancer progression are less
understood.
In this Chapter, we show BET inhibition disrupts ICL repair in Xenopus
laevis egg extract. We show that the defect in repair occurs after approach to the
crosslink by the CMG helicase and DNA incisions. Notably we see BET inhibition
reduces the recruitment of translesion polymerases and subsequent DNA
synthesis. We show BET inhibition blocks the recruitment of the resection
protein, CtIP, to the crosslink, and depleting CtIP mimics the defects observed
under BET inhibition. Altogether, these results implicate BET proteins in ICL
repair, and establish CtIP as a potential regulator of translesion synthesis.

5.2 Methods and Materials
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Antibodies, Immunodepletion, and Immunoprecipitation
FANCD2, Slx4, FANCM, Cdc45, Rev1, Rev7, and PCNA antibodies were produced
previously from New England Peptide in the laboratory of Johannes Walter.
Phosphorylated Chk1 antibodies were purchased from Cell Signaling (#2341). BRD4
antibodies were produced by New England Peptide. Histone H3 antibodies were
purchased from Thermo Fisher (PA5-16183). CtIP antibodies were gifted from Richard
Baer. For depletion experiments, 10 µL of NPE was incubated with 4 µL of Protein-A
Sepharose Fast Flow beads (GE Healthcare) that were pre-bound with either 16 µL of
pre-immune (mock) or αCtIP serum for 1 hour at 4°C. NPE underwent two rounds of
immunodepletion, before use. HSS was subject to one round of depletion, and CtIPdepleted HSS was used for both mock- and CtIP-depleted NPE.

Replication Reactions
pICL was developed as described previously(76). HSS was supplemented with ATP
Regeneration Mix (ARM; 6.5 mM phosphocreatine, 0.65 mM ATP, and 1.6 µg/mL
creatine phosphokinase) and 10 µM nocodazole, while NPE was supplemented with
ARM and 3.5 mM DTT. pICL was incubated in HSS for 20 minutes at room temperature
(RT) then supplemented with NPE to induce replication. The final plasmid concentration
in each reaction was 2.5-5 ng/µL. Once NPE is added, reactions are stored at room
temperature (RT). Where indicated, reactions were supplemented with 300 µM JQ1
(Sigma), 1.5 mM I-BET762 (Selleck Chem) or 0.3 µCi/µL α32P[dATP]. For radioactive
reaction time points, 1 µL of reaction was diluted 6-fold in replication stop dye (3.6%
SDS, 18mM EDTA, 90 mM Tris pH 8, 90 mg/mL Ficoll, 3.6 mg/mL Bromophenol Blue)
and treated with 20 mg proteinase K overnight at RT before agarose gel electrophoresis.
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For repair gel analysis, plasmids were isolated by phenol/chloroform extraction followed
by ethanol precipitation and digested with either HincII (New England Biolabs) or HincII
and SapI (New England Biolabs).

Chromatin Immunoprecipitation
ChIP was performed as described previously(130). Briefly, reaction samples were
crosslinked in ELB containing 1% formaldehyde. Crosslinking was stopped with the
addition of 125 mM glycine and excess formaldehyde was removed with a Micro BioSpin 6 chromatography column (Bio-Rad). Samples were sonicated (Diagenode
Bioruptor UCD-600 TS) and immunoprecipitated with the indicated antibodies.
Crosslinks were then reversed, and the resulting DNA was isolated by phenol/chloroform
extraction and ethanol precipitation. Total (INPUT) and recovered DNA were analyzed
by qPCR. The following primers were used (Figure 5.1A):
ICL: AGCCAGATTTTTCCTCCTCTC and CATGCATTGGTTCTGCACTT
FAR: AACGCCAATAGGGACTTTCC and GGGCGTACTTGGCATATGAT

Incision Assay
Incisions were analyzed as described previously(195). Briefly, pICL and a control
plasmid (pQuant) were pre-labeled with α32P[dATP] via nick translation and replicated as
described above. At the indicated time points, DNA was extracted by phenol/chloroform
precipitation and ethanol precipitation, then digested with HincII. After digested, DNA
was again purified and suspended in alkaline loading buffer (50 mM NaOH, 1 mM EDTA,
2.5% Ficoll-400, 0.025% bromocresol green). Samples were loaded onto a 1% agarose
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gel and separated under denaturing conditions (50 mM NaOH, 1 mM EDTA) for 18
hours at 0.85 V/cm. The gel was then dried and visualized by autoradiography.

Sequencing Gel Analysis
Sequencing gel assays were preformed as described previously(76). Briefly, pICL was
replicated as described above in the presence of α32P[dATP]. At the indicated time
points, DNA intermediates were isolated and purified by phenol/chloroform extraction
and ethanol precipitation. Purified DNA was then digested with AflIII (New England
Biolabs). Digestion reactions were stopped by the addition of 0.5 volumes of stop
solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene
cyanol). Resulting DNA was then resolved using a 7% denaturing polyacrylamide gel
and visualized by autoradiography.

Plasmid Pull-Down
Plasmids were isolated from extract as described previously(80). Briefly, reaction
samples were added to LacI-coupled magnetic beads (Dynabeads M-280; Invitrogen)
suspended in LacI pull-down buffer (10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM MgCl2,
250 mM sucrose, 0.25 mg/mL BSA, and 0.02% Tween 20). Samples were rotated at 4°C
for 20 minutes, washed three times with LacI wash buffer (10 mM HEPES pH 7.7, 50
mM KCl, 2.5 mM MgCl2, 0.25 mg/mL BSA, and 0.02% Tween 20), dried, and
resuspended in 2x SDS buffer (100 mM Tris-HCl pH 7.5, 20% glycerol, 4% SDS, 200
mM β-mercaptoethanol, and 0.2% bromophenol blue). DNA-bound proteins were then
resolved by SDS-PAGE, and visualized by Western blotting with the indicated
antibodies.
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5.3 Results
5.3a BET inhibition disrupts ICL repair
To determine whether BET proteins have a role in inter-strand crosslink (ICL)
repair, plasmids containing a single inter-strand crosslink (Figure 5.1A; pICL) were
replicated in in the presence of α-32P[dATP] using extracts supplemented with buffer or
the BET inhibitor, JQ1. DNA intermediates were isolated at the indicated times, resolved
by agarose gel electrophoresis, and visualized by autoradiography (Figure 5.1B). In
buffer-treated reactions, replication forks converged at the crosslink (purple arrow) by 20
minutes, and reversed fork(172) (blue arrow) and sigma structures(78) (broken/incised
forks, red arrow) were present by 60 minutes. DNA ends from broken or incised
intermediates were then processed and underwent homologous recombination-mediated
repair, resulting in a large number of high-molecular weight branched intermediates by
120 minutes (green arrow). The addition of JQ1 had little or no effect on the efficiency of
DNA synthesis (Figure 5.1C). However, JQ1 treatment resulted in the persistence of
reversed forks and sigma structures, as well as a decrease in the formation of highlybranched intermediates (Figures 5.1D-F). Similar results were obtained with a separate
BET inhibitor, BET-762 (Figure 5.1G). A portion of the high-molecular weight
intermediates is resolved into discreet open-circular and supercoiled plasmid products.
These fully repaired plasmids restore a SapI recognition sequence that spans the site of
the crosslink. Consistent with the observed repair defects, the addition of JQ1 reduced
the amount of SapI-digested products over time (Figures 5.1H-I). Together, these results
show that BET inhibition disrupts ICL repair at a step upstream of homologous
recombination.
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5.3b BET inhibition blocks ICL repair downstream of incisions
We then wanted to identify the step in ICL repair that was defective during BET
inhibition. We saw the fraction of ubiquitylated FANCD2, as well as the level of
phosphorylated Chk1 was decreased in the presence of JQ1 (Figures 5.2A-C). This
suggests a defect in overall damage signaling events during BET inhibition.
We then assayed levels of DNA-bound cdc45, a member of the CMG replicative
helicase, by chromatin immunoprecipitation (ChIP) (Figure 5.2D). The CMG helicase
must be unloaded to facilitate approach to the crosslink, one of the first steps of ICL
repair(80). Cdc45 binding was relatively unchanged with JQ1, suggesting that helicase
unloading occurs normally. The next major step of ICL repair is FANCD2-dependent
DNA incisions on either side of the crosslinked nucleotide(195). We observed similar
levels of DNA-bound FANCD2 by ChIP in buffer- or JQ1-treated reactions (Figure 5.2E).
Additionally, FANCD2-dependent incisions occurred in both reaction set ups, although
slightly delayed in the presence of JQ1 (Figures 5.2F-G). However, we noticed retention
of both FANCM and Slx4 with JQ1-treatment (Figures 5.2H-I). Both of these proteins
play a role in coordinating repair of the crosslinked lesion, and their retention is likely a
bi-product of unresolved repair. Together, these results suggest a defect in ICL repair
downstream of incisions.

5.3c JQ1 treatment impairs the recruitment of TLS polymerases
To analyze nascent strand dynamics, we performed a sequencing gel with buffer
or JQ1-treated reactions(76) (Figures 5.3A-B). In both buffer- and JQ1-treated reactions,
approach to the crosslink (-20 to -40 products) mostly occurred within 60 minutes (Figure
5.3B; compare lanes 1-2 and 6-7). JQ1-treated reactions had a slight delay in approach,
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Figure 5.2. BET inhibition blocks ICL repair downstream of incisions. (A) pICL was replicated in extract
supplemented with buffer control or the BET inhibitor, JQ1. Samples were withdrawn at the indicated time points
and analyzed by Western blot with the indicated antibodies. (B-C) Quantification of ubiquitinated FANCD2 (B) and
phosphorylated Chk1 (C) from (A). (D-E) pICL was replicated in extract supplemented with buffer control or JQ1.
Samples were withdrawn for ChIP at the indicated times points with the indicated antibodies. (F) Schematic of
incised DNA around the ICL. (G) pICL and a control plasmid (pQuant) were pre-labeled with α32P[dATP] by nick
translation and purified. These plasmids were then replicated in extract supplemented with buffer control or JQ1.
Samples were withdrawn at the indicated time points for incision assay (see Methods). (H-I) pICL was replicated
in extract supplemented with buffer control or JQ1. Samples were withdrawn for ChIP at the indicated times
points with the indicated antibodies.

106

A
AflIII

AflIII
ICL

Rightward
Fork

Leftward
Fork

105 – 125 nt

-20 to -40
(Approach)

144 nt

-1

145 nt

Insertion Product

685 nt

Extension Product

B

DMSO
20

60

JQ1

90 120 180 20

60

90 120 180 min

Extension products

Leftward
Fork

-2/-1/0 products
-2/-1/0 products

Righward
Fork

-20 to -40
products
1

2

3

4

5

C

6

7

8

9

10

D
120
100
80
60
40
20
0

-2/-1/0 Products

Buffer
JQ1
0

50

100

150

Time (min)

200

Relative Intensity

Relative Intensity

Extension Products
120
100
80
60
40
20
0

Buffer
JQ1
0

50

100

150

200

Time (min)

Figure 5.3. JQ1 treatment impairs DNA synthesis prior to and past the incised crosslink. (A) Schematic for
nascent strand analysis. (B) pICL was replicated in the presence of α32P[dATP] in extract supplemented with
buffer control or the BET inhibitor, JQ1. Samples were withdrawn at the indicated time points. The DNA was
purified, digested with AflIII, and analyzed by gel electrophoresis and autoradiography. (C-D) Quantification of
extension products (C) and -2/-1/0 products (D) from (B).

107

similar to the slight increase in cdc45 retention in Figure 5.2D. We observed a significant
accumulation of -2/-1 and insertion products in JQ1-treated reactions, as well as a
decrease in extension products (Figures 5.3C-D). Together, these results suggest that
BET inhibition blocks DNA extension prior to and past the incised crosslink.
Translesion (TLS) polymerases are required to extend the incised DNA strand
past the unhooked crosslink(196). To assay the recruitment of TLS polymerases, pICL
was replicated in buffer- or JQ1-treated reactions and plasmid bound proteins were
isolated by plasmid pulldown. As expected, JQ1-treatment resulted in the complete
abolishment of DNA-bound BRD4 (Figures 5.4A-B). Interestingly, JQ1-treatment also
significantly reduced the recruitment of both Rev1 and Rev7 polymerases to pICL
(Figures 5.4A, C-D).
A potential signaling event for the recruitment of TLS polymerases to sites of
damage is mono-ubiquitinated PCNA(198). Therefore, we were curious about PCNA
dynamics in the presence of JQ1. In buffer treated reactions, mono-ubiqiutinated PCNA
was present on pICL up to 45 minutes. Surprisingly, JQ1-treated reactions retained
mono-ubiquitinated PCNA up to 90 minutes (Figure 5.4E). Together, these results
suggest that the signaling for TLS recruitment is retained in JQ1-treated reactions;
however, the physical recruitment of TLS polymerases is defective.

5.3d BET inhibition prevents CtIP localization, which is critical for ICL repair
The roles of DNA end resection in ICL repair are still being discovered. CtIP, a
major resection protein, has been implicated in ICL repair(199-201) at steps downstream
of DNA incisions. Notably, we previously showed a defect in the DNA recruitment of CtIP
under JQ1 treatment in DNA double strand break repair (Chapter 4). When BET proteins
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are inhibited by JQ1 in pICL reactions, we observe a substantial reduction in CtIP
recruitment to the crosslink by ChIP (Figure 5.5A). To formally implicate CtIP in the
repair of ICLs, we immunodepleted extract of CtIP (Figure 5.5B) and replicated pICL in
either mock- or CtIP-depleted extract (Figure 5.5C). We saw a slight increase in
reversed fork structures, a substantial increase and retention of sigma products, and an
overall decrease in high molecular weight intermediates when CtIP was depleted
(Figures 5.5 D-F). Notably, the defects seen under CtIP-depleted conditions mimic BET
inhibited reactions (compare Figures 5.1B and 5.5C), suggesting that CtIP mislocalization is the major consequence of BET inhibition. In Chapter 4, we identify the first
known complex containing both CtIP and BRD4. Therefore, a similar mechanism could
be occurring in ICL repair, where BRD4 and potentially other BET proteins are
responsible for the DNA-localization of CtIP. Future work will aim to uncover the
regulation of CtIP in ICL repair, particularly understanding the role, if any, resection plays
in the recruitment of TLS polymerases.

5.4 Discussion
In this Chapter, we show that inhibition of the BET family of proteins disrupts
inter-strand crosslink repair (Figure 5.1). We then characterize ICL repair in the
presence of BET inhibition, and identify two major defects in translesion synthesis
(Figures 5.3 and 5.4) and CtIP recruitment (Figure 5.5). We immunodeplete CtIP from
extract and demonstrate that loss of CtIP mimics the defects observed with BET
inhibition (Figure 5.5C). This result suggests that CtIP is critical for TLS synthesis, and
BET proteins regulate CtIP recruitment to DNA.
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Reports have identified FANCD2 as an interacting partner of CtIP. This
interaction is likely stabilized by ubiquitinated-FANCD2, and a model has been proposed
that Ub-FANCD2 helps tether CtIP to ICL lesions to induce resection and antagonize
non-homologous end joining(199, 200). Interestingly, we observe less Ub-FANCD2 in
JQ1-treated reactions (Figure 5.2A), suggesting that preventing CtIP localization
reduces the stability of this modification. Since JQ1 prevents the DNA localization of
BET proteins, we propose a model in which BET proteins are critical for the initial
recruitment of CtIP to DNA, and then interactions with Ub-FANCD2 help stabilize CtIP at
the crosslink. How BET proteins are involved in the interaction between CtIP and
FANCD2 is likely to be explored in future studies.
The findings in this Chapter are similar to Chapter 4 in regards to the relationship
between BET proteins and CtIP. However, we see a separate functional consequence of
BET inhibition in the ICL system compared to the DSB system in Chapter 4. Although
dysregulation of CtIP may be a common mechanism in both systems, we see a clear
defect in TLS recruitment and synthesis in ICL repair. These proteins are likely not
involved in DSB repair, and thus not observed in Chapter 4. This finding presents an
intriguing possibility that CtIP-mediated resection precedes, and is critical, for TLS
activation. Future work will uncover the mechanisms behind CtIP-mediated resection in
the repair of ICLs, and how this process is connected to TLS synthesis.
In Chapter 4, we show a novel interaction between BRD4 and CtIP, as well as
with the chromatin remodeling protein BRG1. How BRG1 regulates ICL repair is still
unknown; however, due to its central role in regulating RAD51 (Figure 4.7G), we would
expect, at the minimum, a defect in recombination.

112

The findings in this Chapter highlight the importance of BET proteins and CtIP in
ICL repair. Although CtIP is widely implicated in many DNA repair processes, we add
more mechanistic insight into why CtIP is important for ICL repair. Future work will
uncover more of this mechanism, which will further our knowledge of DNA repair biology.
Additionally, we show BET proteins help coordinate repair of ICLs, which is not
connected to their established roles in transcription regulation. This result, as well as the
findings of Chapter 4, helps cement the importance of BET proteins in DNA repair, and
further explains the HR-deficiency seen in JQ1-treated cells. Importantly, crosslinking
therapies are commonly used as chemotherapeutics for HR-deficient cancers. Although
monotherapy of BET inhibitors has shown little efficacy in clinic(202), the results of this
study suggest combinational treatments with BET inhibitors and crosslinking agents
should be explored.
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Chapter 6: Concluding Remarks
During my graduate work, I developed two novels systems using Xenopus egg
extract. The first of which utilized nucleoplasmic extract derived from interphase eggs. I
showed this extract is the first Xenopus egg extract to support RNAPII-mediated
transcription (Chapter 2). This was a profound discovery that has led to several projects
in the Long laboratory. I also developed a system to study the repair of DNA double
strand breaks using restriction enzymes (Chapter 4). After establishing this system, I
characterized the repair of DSBs in extract and showed they undergo regulated repair,
similar to that observed in cellular systems. Again, this system is being used for several
other projects in the Long laboratory. I am proud to have established these systems, and
I hope they will be used extensively in the future to understand the biology behind the
fundamental processes of transcription and DNA repair.
Using our transcription system, I identified the first molecular connection
between two major proteins involved in genome stability, BRD4 and BRCA1 (Chapter 3).
I look forward to future work in advanced model systems that will expand on this
discovery and hopefully identify the biological significant of this novel regulation. The
tumor suppression activity of BRCA1 is largely tied to estrogen-responsive tissues.
Therefore, it would be interesting to try and observe this connection in breast models.
We have preliminary data connecting BRCA1 and BRD4 to p300, which is an important
regulator of estrogen receptor alpha activity in these tissues. This data supports an
overall model in which BRCA1-mediated suppression of p300 reduces BRD4 binding to
DNA, and that when these mechanisms are disrupted, dysregulation of the
transcriptome and enhanced genomic instability occur.
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I then identified a previously unknown role for BRD4, and potentially other BET
proteins, in the regulation of DSB repair and inter-strand crosslink repair (Chapters 4 and
5). A common mechanism between both repair pathways is dysregulation of the DNA
end resection protein, CtIP. BRD4 had previously been shown to control the transcription
of CtIP, but my results suggest that this regulation can occur at the gene and protein
level. Indeed, I found a novel interaction between BRD4 and CtIP, along with the
chromatin remodeling protein, BRG1. It is important to reiterate that these mechanisms
occurred in the absence of global gene expression, formally showing that BET proteins
have a direct role in repair in addition to their previously identified roles in regulating the
transcription of DNA damage genes. I believe these findings will be of great interest to
the fields of DNA repair and BET biology, and I hope that future work will be able to
extrapolate these findings to identify cancer treatments.
How BRCA1 fits into the models we propose for our DSB systems is yet to be
determined. The negative regulation of BRD4 by BRCA1 we see in our transcription
studies may not be observed in our DSB system. Indeed, since we show BRD4 is
important for HR-mediated repair, we would expect BRCA1 and BRD4 to work together
rather than act antagonistically in the setting of DNA repair. However, we do see a
decrease in DNA-bound BRD4 soon after DSB induction, which we believe occurs once
BRD4 coordinates BRG1 and CtIP to the site of damage. It is possible that when BRCA1
is recruited to sites of damage it helps promote the removal of BRD4 from DNA.
Additionally BRCA1 could be acting upstream of BRD4 recruitment, preventing the
recruitment of a BRD4-CtIP complex until DNA damage is sensed. I am excited to see
what future studies reveal about the regulation between BRD4 and BRCA1 in regards to
DNA repair. These two proteins have been studied extensively; however, new molecular
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functions and regulation are continually being discovered. I hope the results seen in this
dissertation help further the fields of BRCA1/BRD4 biology and ultimately lead to a more
complete understanding of their role in preserving genome integrity.
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